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Background: Synthetic glucocorticoids are commonly used in reproductive medicine. Fetal organ systems are
highly sensitive to changes in the intrauterine environment, including overexposure to glucocorticoids. Struc-
tural and functional alterations resulting from such changes may persist throughout life and have been asso-
ciatedwithdiverse diseases.One system that could beparticularly sensitive to fetal glucocorticoid overexposure
is the hypothalamic-pituitary-adrenal (hpa) axis. Many human studies have investigated this possibility, but a
systematic review to identify consistent, emergent findings is lacking.
Methods:Wesystematically review49human studies, assessing the effects of intrauterine exposure to synthetic
glucocorticoids on fetal, neonate, and infant hpa function.
Results: Study quality varied considerably, but the main findings held true after restricting the analyses to higher-
quality studies: intrauterineexposure to syntheticglucocorticoids reducesoffspringhpaactivityunderunstimulated
conditions after pain but not pharmacological challenge. Although reduced unstimulated hpa function appears to
recover within the first 2 wk postpartum, blunted hpa reactivity to pain is likely to persist throughout the first 4
months of life. There is some evidence that the magnitude of the effects is correlated with the total amount of
glucocorticoidsadministeredandvarieswiththetimeintervalbetweenglucocorticoidexposureandhpaassessment.
Conclusions: This systematic review has allowed the demonstration of the way in which intrauterine exposure
to various regimens of synthetic glucocorticoids affects various forms of hpa function. As such, it guides future
studies in terms of which variables need to be focused on in order to further strengthen the understanding of
such therapy, whilst continuing to profit from its clinical benefits. (Endocrine Reviews 30: 753–789, 2009)
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I. Introduction
A. Background
Synthetic glucocorticoids are commonly administeredduring human fetal development. For example, they
successfully reduce morbidity and mortality in preterm
infants by accelerating fetal lung maturation (1–3) (see
Section II.A). However, major concerns have arisen con-
cerning the safety of such therapybecause there is evidence
fromanimal andhuman studies that intrauterine exposure
to synthetic glucocorticoids may compromise health and
development in affected offspring (4–7). Hence, under-
standing the impact of synthetic glucocorticoids on fetal
organ systemsmay help to reappraise costs and benefits of
different forms of such therapy.
Over recent years, early programming by glucocorti-
coids has become a topic of particular interest in the sci-
entific community, and the issue has grown to a matter of
public concern. The ongoing European Project on Glu-
cocorticoid Programming in Early Life and its Impact on
Adult Health (EUPEAH), funded by the European Com-
mission, is one example of large-scale research in this field,
investigating in nonhuman primates whether intrauterine
overexposure to glucocorticoids is a key trigger of adult
disease programming (e.g., Ref. 8).
Synthetic glucocorticoids are agonists of the glucocor-
ticoid receptor [GR (the symbol approved by the Human
Genome Organization Nomenclature Committee is
NR3C1)] and predominantly act via genomic effects me-
diated by the GR, a nuclear transcription factor (for de-
tailed description, see Refs. 9 and 10). Because of its
markedGR expression, the fetal lung is one of the primary
targets of synthetic glucocorticoids administered during
fetal development. The effects of synthetic glucocorticoids
on the fetal and neonatal lung have been reviewed else-
where (e.g., Refs. 11 and 12), as has their impact on other
organ systemswithhighGRexpression (13, 14), including
kidney and brain (e.g., Refs. 15–17). Also, the clinical
outcomes that are potentially related to structural and
functional changes in the brain after intrauterine exposure
to synthetic glucocorticoids, including cognitive, psycho-
logical, or behavioral development, have been brought
together in previous works (5, 7). In this article, we sys-
tematically review the scientific literature on human stud-
ies that assessed the effects of intrauterine exposure to
synthetic glucocorticoids on the hypothalamus-pituitary-
adrenal (hpa) axis.
B. Rationale for this review
Understanding the effects of intrauterine exposure to
synthetic glucocorticoids on fetal and infant hpa axis is
important for the following reason: fetal organ systemsare
highly sensitive to changes in the intrauterine environ-
ment. Structural and functional alterations that occur as a
result of such changes persist throughout life and influence
development and health (18). It has been broadly docu-
mented inanimals that thehpaaxis is particularly sensitive
to early life factors, among which glucocorticoids play a
key role (19). In humans, comparable effects of glucocor-
ticoids on the hpa axismight be clinically relevant because
1) synthetic glucocorticoids are widely used in reproduc-
tive medicine; and 2) altered hpa axis activity has been
linked to a number of adverse health outcomes and dis-
eases throughout life in humans (20). Much of what we
currently know about the effects of intrauterine exposure
to synthetic glucocorticoids on hpa axis function comes,
due to methodological and ethical constraints, from ani-
mal studies (4, 18, 21). To the best of our knowledge,
although a considerable number of human studies cover-
ing this issue have been published over the last three de-
cades, no concise review has brought these findings to-
gether to present a comprehensive picture on the current
research in the field. Also, findings from human studies
have not been included in recent reviews of animal find-
ings on this topic.
C. Objectives
The objective of this article is to systematically review
scientific publications on the effects of intrauterine expo-
sure to synthetic glucocorticoidsonoffspringhpa function
in humans. Our hypothesis was that in humans, intrauter-
ine exposure to synthetic glucocorticoids reduces hpa axis
function in the offspring.
Before presenting the methods of the systematic review
and the findings from the relevant articles themselves, we
will 1) give information on the clinical administration of
synthetic glucocorticoids during pregnancy and its histor-
ical perspective; 2) summarize the physiological and phar-
macological factors regulating fetal drug exposure; and 3)
synthesize the current understanding of the functional en-
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tity of the fetal hpa axis, which is somewhat different from
the postnatal hpa axis or its better-characterized adult
counterpart (22).
II. Pharmacological and
Physiological Background
A. Clinical treatment with synthetic glucocorticoids
during pregnancy and its historical perspective
Glucocorticoids modulate a wide variety of physiolog-
ical processes. They influence lipid, protein, and carbo-
hydrate metabolism, and regulate cardiovascular, neuro-
biological, and immunological function. Many of these
effects function tomaintain homeostasis andmediate cop-
ing with and adaptation to stressful situations (23). Given
the crucial role of endogenous glucocorticoids in control-
ling most organ systems, their synthetic analogs are
broadly used in clinical practice for a large variety of clin-
ical conditions.
Specifically during fetal development, glucocorticoids
stimulate surfactant production and influence structural
changes, growth factors, lung fluid metabolism, antioxi-
dant enzymes, and adrenergic receptors in the maturing
fetal lung. In late gestation, fetomaternal cortisol secretion
increases to complete pulmonary maturation and prepare
the fetal lungs for extrauterine life (11, 24). Accordingly,
preterm infants are endangered with pulmonary immatu-
rity, which predisposes to respiratory distress syndrome
(RDS). Indeed, premature birth is associated with an in-
creased risk of neonatal mortality and morbidity, includ-
ing RDS. Due to their potency in maturating fetal organ
systems, synthetic glucocorticoids are commonly used in
cases of high-risk preterm delivery to accelerate fetal lung
maturation. Seven to 10% of all pregnancies in North
America are under such risk (25). In addition, during
gestation, synthetic glucocorticoids are given for several
other clinical conditions of the mother or the fetus, in-
cluding allergies, asthma, and congenital adrenal hy-
perplasia (CAH).
Gestational glucocorticoid therapy to prevent RDS
goes back to the pioneeringwork of Liggins (26) in the late
1960s, who demonstrated that preterm lambs exposed to
glucocorticoids in utero have less severe respiratory dis-
tress than would be anticipated, suggesting that glucocor-
ticoids hold lung maturational properties. In their subse-
quent landmark randomized placebo-controlled study,
Liggins andHowie (27) confirmed this observation in hu-
mans, demonstrating a more than 2-fold decrease in the
incidence of RDS and a 5-fold reduction of neonatal death
in premature infants exposed to betamethasone in utero.
Since this initial investigation, numerous randomized tri-
als examining the effects of antenatal glucocorticoid ad-
ministration in humans have reported positive results. A
meta-analysis of 15 randomized trials carried out between
1972 and 1994 showed that the use of antenatal cortico-
steroids resulted in an overall reduction of complications
associated with preterm delivery, such as neonatal RDS,
periventricular hemorrhage, necrotizing enterocolitis,
and, most importantly, neonatal mortality (28). These re-
sultswere again confirmed in a recent review that included
21 studies (3). Accordingly, in 1994, the National Insti-
tutes of Health (NIH) Consensus Developmental Confer-
enceon theEffects ofCorticosteroids for FetalMaturation
on Perinatal Outcomes concluded that all fetuses between
24 and 34 wk gestation at risk of preterm delivery should
be considered candidates for antenatal treatmentwith glu-
cocorticoids (25). Recommended treatment consisted of
two doses of 12 mg betamethasone given im 24 h apart or
four doses of 6 mg dexamethasone given im 12 h apart.
However, despite the NIH recommendations, the re-
ported beneficial effects of treatment, and its potential to
produce large cost savings in the health care system, ob-
stetricians were slow to incorporate antenatal glucocor-
ticoid use into routine practice. Implementation of treat-
ment has taken 15 yr to rise roughly 10-fold, from 8% in
1985 to 75% in 2000 (29).
In themeantime, antenatal glucocorticoid use in fetuses
at risk of pretermdelivery has become commonpractice to
prevent postnatal RDS. Treatment protocols, however,
remain somewhat inconsistent across institutions and
physicians. If women continue pregnancy after a single
course of glucocorticoid treatment, then in some cases fur-
ther courses are subsequently administered.However, due
to insufficient scientific data, in 2001 the NIH Consensus
Developmental Panel recommended that repeat courses
should not be used routinely until insightful findings are
available (30).
In sum, after hesitant beginnings almost four decades
ago, synthetic glucocorticoids are in the meantime used
broadly in obstetric medicine to treat fetuses at risk of
preterm birth to prevent RDS.
Synthetic glucocorticoids are further administered to
pregnant women due to maternal medical conditions, in-
cluding autoimmune diseases, allergies, and asthma, or
due to fetal needs other than lung maturation, such as
CAH. In contrast to preparation for preterm birth, treat-
ment in the latter cases often begins early in pregnancy and
lasts throughout gestation.
B. Fetal drug exposure
Different synthetic glucocorticoids are used in obstetric
practice. In the studies reviewed, these were in most cases
one of the following: betamethasone, dexamethasone, or
prednisolone. Synthetic glucocorticoids are marginally
different from their endogenous equivalents in chemical
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structure. Prednisolone differs from cortisol by a -1-
dehydro configuration. Dexamethasone and betametha-
sone both have additional 9--fluoro groups, and 16-- or
16--methyl groups, respectively (31). Due to these struc-
tural alterations, synthetic analogs of endogenous glu-
cocorticoids exhibit comparatively intensified potency at
the GR and reduced activity at the mineralocorticoid re-
ceptor [MR (the symbol approved by the HUGONomen-
clature Committee is NR3C2)] (10). Moreover, they vary
among themselves in their pharmacokinetic and pharma-
codynamic properties. These properties are partly deter-
mined by each drug’s specific chemical preparation. This
is clinically relevant because fetal exposure to synthetic
glucocorticoids is generally controlled by the pharmaco-
kinetic and pharmacodynamic characteristics of the spe-
cific drug 1) in the mother, including protein binding,
the manner and extent of drug absorption, its distribu-
tion throughout fluids and tissues, metabolism, and
elimination; and 2) in the fetoplacental unit, including
the amount of drug that crosses the placenta and the
drug’s metabolism, distribution, and elimination in the
fetoplacental unit (32).
1. Pharmacokinetic properties of synthetic glucocorticoids
a. Plasma and biological half-life. Plasma half-life represents
the time that passes until one half of the initial drug con-
centration has disappeared from the blood (33). Beta-
methasonehalf-life inhumanplasma ranges between6.5h
(34) and 9 h (35), depending on the formulation given (see
below). Reported plasma half-life of dexamethasone av-
erages 4 or 4.6 h, after oral administration of dexameth-
asoneor iv injectionofdexamethasone sodiumphosphate,
respectively (36). The half-life of prednisolone, as admin-
istered orally or iv in different preparations, is approxi-
mately 3 h (36). Cortisol itself has a plasma half-life of
about 1.5 h (33).
The duration of measurable biological activity repre-
sented by the biological half-life is longer than plasma
half-life, and synthetic glucocorticoids have been divided
into short-, medium-, and long-acting substances. Al-
though both betamethasone and dexamethasone have
long-acting properties, ranging between 36 and 54 h,
prednisolone belongs to the medium-acting category, and
cortisol to the short-acting category with biological half-
lives of 12–36 h and 8–12 h, respectively (33).
b.Proteinbinding.Thebiologicalactivityofglucocorticoids
is partly determinedby rate and selectivity of protein bind-
ing because only the unbound glucocorticoid fraction is
biologically active. Across several species including hu-
mans, endogenous cortisol binding to corticosteroid bind-
ing globulin [CBG (the symbol approved by the HUGO
Nomenclature Committee is SERPINA6] ranges between
67 and 87%, whereas a further 7 to 19% of total cortisol
is bound to albumin (37), leading to about 95% cortisol
being protein-bound in the plasma. Cortisol binding de-
creases as its concentration increases (38). Prednisolone
binds to both proteins (39): with increasing prednisolone
concentrations frombelow200 toabove700g/liter, pro-
tein binding decreases nonlinearly from 95 to 60% (40).
Conversely, in human plasma, betamethasone and dexa-
methasone bind predominantly to albumin, which has
high capacity but low affinity for ligating, whereas both
steroids bind onlymarginally toCBG (38, 41).Dexameth-
asone displays higher protein affinity than betametha-
sone; plasma binding of these synthetic glucocorticoids is
75 and 60%, respectively, and is quite constant across a
wide concentration range (36, 38, 42). It is unknown
whether different preparations of synthetic glucocorti-
coids have variable effects on protein binding.
c. Glucocorticoid potency. The primary synthetic glucocor-
ticoids, including betamethasone and dexamethasone, act
predominantly via genomic effectsmediated by theGR, in
accordance with its nuclear transcription factor function
(9, 10). The potency of a synthetic glucocorticoid, i.e., a
measure of its activity in a biological system, depends on
its affinity for its receptor and its efficacy. Genomic glu-
cocorticoid potency of betamethasone was reported to be
moderately higher than that of dexamethasone, with both
steroidshavinga25-foldhigher, andprednisolonea4-fold
higher, affinity to the GR than does cortisol. At higher
doses, when nonspecific, nongenomic effects that are me-
diated by steroid-selective membrane receptors come into
play, potency of dexamethasone is still 5-fold stronger
than potency of prednisolone, whereas potency of beta-
methasone is lower than that of prednisolone (43). Affin-
ity to theMRwas shown to be relatively low in each of the
three synthetic preparations, with prednisolone display-
ing themost pronouncedmineralocorticoid potencyof the
three (10).
d. Phosphate or acetate. Betamethasone is available in two
differentprodrug formulations: a fast-releasingphosphate
ester and a slow-releasing, dual-acting suspension con-
tainingphosphate andacetate ester. The two formulations
differ in their pharmacokinetic characteristics in human
plasma, with the dual formulation being linked to an ap-
proximately 30% longer half-life than the phosphate ester
(34, 35), raising the possibility of unwanted side effects in
the mother and fetus due to longer exposure. Indeed,
women treated with the suspension containing phosphate
and acetate ester have recently been shown to have an
increased incidence ofmaternal infection (44). In the latter
review, however, effects of the dual formulation of beta-
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methasone were comparedwith effects of dexamethasone
phosphate. It thus remains unanswered as towhether pure
betamethasone phosphate impacts on maternal health in
a similar fashion.Thedifferent prodrug formulationshave
been directly compared in a sheep model where the diver-
gence of effects is even more pronounced, with the dual
formulation being associated with a more than 3-fold
longer half-life than the phosphate ester (45). However,
other researchers did not replicate these findings, demon-
strating relatively short plasma half-lives of 3 h in both
formulations (46).
Interestingly, the dual formulation has been associated
with lower peak maternal and fetal betamethasone con-
centrations, reduced by approximately 50%, when com-
pared with those observed after injection of a similar dose
of the phosphate ester. This finding suggests that, due to
little betamethasone release from the acetate, the dual for-
mulation will have less effect on maternal and fetal func-
tion (46), thereby outweighing the concern about adverse
effects on mother and fetus due to longer half-life.
Taken together, the dual betamethasone suspension
seems to have a longer half-life, whereas the fast-releasing
betamethasone phosphate seems to result in higher peak
concentrations. Both pharmacokinetic properties may be
linked to unwanted side effects. Whether the type of be-
tamethasone formula used in the reviewed studies has in-
fluenced the effects of synthetic glucocorticoids inuteroon
hpa axis needs to be taken into account.
2. Pharmacokinetic properties of synthetic glucocorticoids
in the mother and fetus during pregnancy
Most studies have examined the pharmacodynamic
and pharmacokinetic properties of synthetic glucocorti-
coids in nonpregnant women. However, physiological
changes that occur during pregnancy, such as changes in
the renal, gastrointestinal, cardiovascular, and immune
system (47), lead to variations in the processes of absorp-
tion, distribution in fluids and tissues, metabolism, and
elimination of different kinds of drugs, including synthetic
glucocorticoids (32, 47–50). Therefore, findings from
nonpregnant women may not be transferable to pregnant
women.
In accordance with this assumption, Petersen et al. (51)
demonstrated that betamethasone clearance and volume
of distribution are higher in pregnant than in nonpregnant
women, whereas the half-life remained unchanged. Fur-
thermore, pharmacokinetic properties seem to differ be-
tween pregnancies, for instance varying with the plurality
of birth (35). Accordingly, the half-life of betamethasone
in mothers with twin pregnancies was shown to be signif-
icantly shorter than in mothers with singleton pregnan-
cies. Interestingly, pharmacokinetic characteristics of be-
tamethasone are different in mother and fetus, as studied
in ewes. It is clinically relevant that after injection into
maternal muscle tissue, as is common practice in obstet-
rics, betamethasone half-life is longer in fetal than in ma-
ternal circulation, suggesting that fetal drug exposure is
more extensive than would be anticipated from maternal
pharmacokinetic data (52).
Secondary to plasma volume expansion, maternal se-
rum concentrations of albumin decrease progressively
during pregnancy, despite elevatedmaternal albumin syn-
thesis, resulting indecreasedprotein-binding capacity (53,
54). This may be clinically important as the unbound,
biologically active fraction of synthetic glucocorticoids
such as betamethasone or dexamethasone, as they bind
to albumin specifically, subsequently increases. Conse-
quently, because only the unbound drug fraction passes
theplacenta, agreater amountof synthetic glucocorticoids
reaches the fetus as pregnancy proceeds. However, fetal
albumin concentrations gradually increase during gesta-
tion, equaling (55) or even exceeding (56) maternal albu-
min concentrations at term. Therefore, more glucocorti-
coid is bound in fetal plasma, thereby partly reducing the
drug’s biological activity.
It has been argued that enhanced hepatic and renal
elimination in the pregnant female might influence the
concentration of free drug in the mother and fetus. This
protective mechanism has, however, not yet been proven
for synthetic glucocorticoids. Moreover, there is some ev-
idence that the fetus itself is capable of metabolizing and
eliminating drugs, althoughmost enzymatic processes are
immature (32).
3. Transduction frommother to fetus: placental transfer of
synthetic glucocorticoids
Drug/substancepermeationacross theplacental barrier
is determined by diverse factors including drug properties,
placental characteristics, and additional maternal and fe-
tal influencing factors (57).
Placental hydroxysteroid (11) dehydrogenase 2 [11-
HSD2 (the symbol approvedby theHUGONomenclature
Committee is HSD11B2] represents one key enzyme that
selectively regulates the transplacental passage of glu-
cocorticoids (6). Therefore, although endogenous glu-
cocorticoids are highly lipophilic and rapidly cross the
placenta, normally the fetus has much lower concentra-
tions than its mother (58, 59). Located in placental syn-
cytiotrophoblast (60), 11-HSD2 catalyzes the rapid con-
version of cortisol and corticosterone to inert 11-keto
forms as shown in vitro and in vivo, forming a potent
albeit incomplete barrier (61). However, transplacental
passage differs considerably between endogenous and
synthetic glucocorticoids (62). After a 1-h incubation,
more than 95% of corticosterone, 63% of cortisol, but
only 17% of dexamethasone had been metabolized in
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mammalian cells transfected with 11-HSD2 (60). Fur-
thermore, different pharmaceutical preparations of syn-
thetic glucocorticoids have varying 11-HSD2 metabo-
lism profiles based on their chemical structures. In
contrast to endogenous glucocorticoids, 9-fluorinated
glucocorticoids such as betamethasone and dexametha-
sone showweakoxidasebut strong reductase activitywith
11-HSD2, thereby decreasing local inactivation. Con-
versely, reduction by 11-HSD2 is increased by the -1-
dehydro configuration in prednisolone (31). In accor-
dance with this observation, in an early study, Blanford
andMurphy (63) found that 67% of cortisol and 52% of
prednisolone, but only 2% of dexamethasone and 7% of
betamethasone, were converted by 11-HSD2 to their in-
active 11-keto metabolites in human placental tissue in
vitro. Accordingly, clinical studies demonstrated 10-fold
lower prednisolone (64) but only 3-fold lower betametha-
sone (48, 65) concentrations in fetal compared with ma-
ternal plasma when examining cord and maternal blood.
In a recent investigation, one group monitored placental
metabolismof diverse synthetic glucocorticoids over time,
revealing that betamethasone ismore rapidlymetabolized
than dexamethasone and prednisolone in the human pla-
centa, with their 11-keto metabolites being first observed
after 60, 120, and 240 min, respectively (66). Comparing
rates of inactivation by 11-HSD2 between these three
substances, metabolism of both betamethasone and pred-
nisolone is significantly greater than that of dexametha-
sone (66). Interestingly, synthetic glucocorticoids have
themselves been shown to up-regulate placental 11-
HSD2 activity (67–69) and, hence, to amplify the placen-
tal barrier. However, this up-regulation does not seem to
significantly affect actions of synthetic glucocorticoids in
the fetus (68, 69).
There is evidence that in conjunction with 11-HSD2,
the ATP-binding cassette, sub-family B (MDR/TAP),
member 1 [also known as P-glycoprotein (P-gp), the sym-
bol approved by the HUGONomenclature Committee is
Abcb1] augments the placental glucocorticoid barrier, re-
ducing fetal exposure to elevated levels of glucocorticoids
(70). P-gp removes substances, including synthetic glu-
cocorticoids, from cells by ATP-dependent extrusion (71,
72). P-gp is highly expressed in syncitiotrophoblast cells of
the placenta (73, 74). It has recently been shown that P-gp
activity decreases in the mouse, guinea pig, and human
placenta in late gestation, suggesting that the ability of the
placenta to exclude synthetic glucocorticoids from the fe-
tus decreases in late gestation (73–78).
Once having entered the fetus, synthetic glucocorti-
coids can take effect in the fetus, including the fetal brain.
In adulthood in the rat, P-gp activity at the level of the
blood-brain barrier inhibits betamethasone, dexametha-
sone, and prednisolone from entering the brain (79–83).
However, although present in fetal brain at the end of
gestation in rats, levels of P-gp transcripts are low in the
fetal blood-brain barrier and increase considerablywithin
the first 60 d postpartum (84). Extrapolating from these
findings, the fetal blood-brain barrier would be expected
to be considerably more permeable to synthetic glucocor-
ticoids than theblood-brainbarrier inpostnatal life stages.
Inconclusion, there is readytransplacentalpassageofsyn-
thetic glucocorticoids.Oncehavingpassed theplacental bar-
rier, glucocorticoidsmaybecomeactive in the fetus including
the fetal brain, thereby possibly impacting on the developing
systems that express GR, for example the hpa axis.
C. Ontogeny of glucocorticoid receptors
The primary synthetic glucocorticoids, including beta-
methasone and dexamethasone, act via the intracellular
GR that binds cortisol with low affinity and synthetic
glucocorticoids with high affinity (see Section II.B.1).
According to the broad physiological functions of endog-
enous glucocorticoids (see Section II.A), which progres-
sively occupy GRs after stress or during the circadian rise
(85), GR is expressed inmost organ systems, including the
brain. In the brain, regions of high GR expression include
the amygdala (86), hippocampus (87, 88), and the para-
ventricular nucleus of the hypothalamus (PVNh) (87, 89).
Thehypothalamusprojects via themedian eminence to the
pituitary gland, which also expresses high levels of GR
(90, 91). Thus, GR expression is high in those regions,
namely the amygdala and hippocampus, that regulate
CRH synthesis and release in the PVNh, as well as being
high in the pituitary, which responds to CRH with in-
creased ACTH release into the circulation. In short, GR is
a major modulator of the hpa axis, which is the major
source of endogenous glucocorticoid hormones.
Whether synthetic glucocorticoids administeredduring
gestation exert effects on the fetal hpaaxis thusdependson
the stage of maturation of GR expression in the fetal hpa
axis or those regions involved in its regulation, including
the hippocampus (92, 93). In mice, from around midges-
tation until term, the fetal zone of the placenta expresses
GRmRNAtoamuchgreater extent thandoes thedecidual
zone (94); this suggests that synthetic glucocorticoidsmay
become active at the placental level at an early develop-
mental stage. In thehuman fetal hippocampus,GRmRNA
expression was detected as early as 24 wk gestation and
might emerge even before that time; that is, the receptor is
present in thefetusat thetimewhensyntheticglucocorticoids
are given to the mother to accelerate fetal lung maturation
(95).Todate, virtuallynothing is knownabout theontogeny
of GR in the fetal PVNh or pituitary in humans.
In sheep that have a pattern of prenatal brain develop-
ment showingcertain similarity tohumansandhaveahigh
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degree of neurological maturity at birth (96), it has been
shown that inmid-late gestation, high levels ofGRmRNA
are present in the fetal cerebral cortex, hippocampus, and
PVNh (97). In the mouse fetus, GR gene expression in
hypothalamus and pituitary was detected around midg-
estationwith striking increases in the pituitary toward the
end of gestation, when glucocorticoid production rises. In
contrast, GRmRNAexpression remains low in themouse
fetus adrenals throughout gestation (94). In the common
marmoset (Callithrix jacchus), GR expression levels in the
hippocampus and PVNh of neonates are similar to those
of adults. This indicates that brain GR expression is ap-
parently already mature at birth and implies that fetal GR
expression will also be considerable, at least in those spe-
cies that give birth to relatively mature offspring (98).
This early presence of GRs in the fetal brain, combined
with the pharmacokinetic evidence that syntheticGRago-
nists administered to the mother enter the fetus, including
the fetal brain, indicate that brain GRs will be substan-
tially activated in the fetus after glucocorticoid treatment.
As a result of this, offspring hpa axis function could be
acutely or chronically influenced (99).
D. Development of hpa axis
The fetal hpa axis exhibits a number of important dif-
ferences from the hpa axis at various postnatal life stages,
which has been described extensively elsewhere (e.g. Ref.
22). The hypothalamus, pituitary, and adrenal gland are
each subject to dynamic morphological and/or functional
changes as they mature, but do attain adult status and
function soon after birth. Furthermore, the placenta is a
principal regulator of the fetal hpa axis (for details see
below).Thus, itwouldbemoreappropriate touse the term
“hpa axis of the fetoplacental unit” or “fetal hypothalamic/
placental-pituitary-adrenal (hppa) axis.” Because the hpa
axis is a well-defined concept in literature, we stick to the
term “fetal hpa axis” which, however, includes reciprocal
effects between the fetal hpa axis and the placenta.
The present knowledge about the developmental, in-
cluding functional, biology of the human and nonhuman
primate fetal hypothalamus, pituitary, and adrenal cortex
hasbeen reviewed indetail elsewhere (100–103).Basedon
these works, in the following section, we summarize func-
tion, anatomy, and development of the embryonic and
fetal hpa axis throughout gestation.
1. Hpa axis function
Hormones produced by the human fetal adrenocortical
system control intrauterine homeostasis and the matura-
tion of fetal organ systems necessary for extrauterine life,
including lungs, liver, and gut, and establish the estrogenic
milieu of pregnancy. Therefore, adequate development
and function of the fetal adrenocortical system and struc-
tures involved in its regulation are critical to ensure fetal
maturation. Furthermore, the endocrine system itself is
subject to diverse morphological and functional changes
to prepare for extrauterine survival. After birth, themajor
physiological role of the adrenocortical system is to syn-
thesize and secrete glucocorticoids for the maintenance of
metabolic homeostasis and the stress response and min-
eralocorticoids for the maintenance of fluid and electro-
lyte balance (102).
2. Anatomical and functional development of the hpa axis
The human fetal hypothalamus is defined by the sev-
enthweek of gestation (101). CRH-positive fibers exist by
the16thweekof fetal life (104).An intactportal systemfor
the transport of hypothalamic-releasing factors to the pi-
tuitary gland is detectable at 11.5 wk gestation, allowing
the establishment of hypothalamic control over pituitary
corticotropes around midgestation (105). In the pituitary
gland, a rudimentary adenohypophysis can be identified
by 6 wk gestation, maturing within the subsequent 8 wk
(101). Immunohistochemical studies demonstrate the
presence of corticotropes at 7 wk gestation (106) and, in
accordancewith this observation, ACTH secretion occurs
at 8 wk gestation (107). The anlage of the adrenal cortex
is detectable from the fourth week of gestation. By 8 wk,
the embryonic adrenal cortex is clearly identifiablewith its
characteristic zonal partitioning (102).
The primate fetal adrenal cortex ismainly composed of
threemorphologically and functionallydifferent compart-
ments, discerned on the basis of expression of specific ste-
roidogenic enzymes: the fetal, the definitive, and the tran-
sitional zone (102). The former comprises a good portion
of the fetal adrenal cortex, representing the primary site of
growth and steroidogenesis. The fetal zone produces the
androgenic C19 steroid dehydroepiandrosterone sulfate
(DHEA-S), which is quantitatively the principal steroid
product of the primate fetal adrenal gland throughout ges-
tation. The exiguous definitive zone is the likely site of
mineralocorticoid production in late gestation, whereas
the smaller transitional zone has the capacity to produce
glucocorticoids, thus being the precursor of the adult zona
fasciculata (102).
Rapid growth of the fetal adrenal cortex, especially the
fetal zone, begins after 10wk gestation and goes on to term;
by midgestation, the fetal zone clearly dominates. Between
20 and 30 wk, the size and weight of the fetal adrenals dou-
ble, achieving a relative size 10 to 20 times that of the adult
adrenal, further doubling until term (102). By 30 week ges-
tation, the fetal adrenal cells begin to remodel, taking on a
rudimentary appearance of the adult adrenal cortex (108).
Steroidogenic activity starts during early gestation.
Low levels of estriol, indicative of DHEA-S production in
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the fetal adrenals (109), can first be detected in the ma-
ternal circulation after 8 to 10 wk gestation. About 2 to 4
wk later, estriol concentrations in thematernal circulation
increase rapidly up to 100-fold. Subsequently, activity of
the fetal zone continues to increase during the second and
third trimesters, ultimately producing around 200 mg
DHEA-S/d at term (102).
Observations of infants with CAH, as well as in vitro
and in vivo studies, indicate that the fetal adrenals begin to
produce cortisol between 10 and 20 wk gestation, pos-
sibly utilizing progesterone as precursor (102, 110,
111). However, de novo synthesis of cortisol from cho-
lesterol is established fairly late in gestation, leading to
a remarkable increase of cortisol concentrations in the
third trimester (102).
Taken together, hpaaxis structures emerge earlyduring
pregnancy, grow rapidly, and take on steroidogenic ac-
tivity by about 8 to 10 wk gestation.
3. Hpa axis regulation
The fetal hpa axis can be stimulated by acute hypoxia,
systemic hypotension, hemorrhage, psychological stress,
noxious stimuli, and neuropeptides and can be inhibited
by glucocorticoids and vagal stimulation (103). As re-
ported in a series of studies by Giannakoulopoulos et al.
(112, 113), the human fetus can mount hormonal stress
responses to invasive stimuli, with rises in -endorphin,
cortisol, and noradrenaline. Interestingly, fetal stress re-
sponses were shown to be independent of maternal hor-
monal reactions to invasive procedures (114).
Ng and co-workers (103) have illustrated the neuroen-
docrine interaction between the fetal hpa axis and the pla-
centa. In short, ACTH secreted from the fetal pituitary is
the principal regulator of the human fetal adrenal cortex.
However, fetal adrenal development is further influenced
by other elements acting independently or synergistically
with ACTH, including growth factors, transcription fac-
tors, and placental factors includingCRH (102, 115). Pla-
cental CRH was shown to stimulate the production of
proopiomelanocortin and ACTH in the fetal pituitary
(116, 117) and within the placental syncytiotrophoblast
cells (118), thereby regulating growth and function of pi-
tuitary corticotrope cells and adrenal cortex (102, 103).
Because placental and hypothalamic CRH are identical in
immunoreactivity, bioactivity, and structure, it is possible
that both fetal hypothalamic andplacentalCRHstimulate
fetal pituitary, and in a comparable manner. However,
because umbilical venous CRH concentrations were
shown to be higher than arterial levels, circulating CRH
seems to be largely of placental origin (119).
Apart from enhancing adrenal secretion of cortisol,
which in turn reduces the activity of the axis via negative
feedback mechanisms (103, 120), fetal ACTH also stim-
ulates synthesis of DHEA-S (103), which itself is a sub-
strate for placental estrogen synthesis (109). In thebaboon
at least, placental estrogens were shown to induce the in-
activation of cortisol to cortisone in the placenta. This
reduces fetal exposure to maternal cortisol and thus de-
creases inhibition of the fetal hpa axis via negative feed-
back by maternal cortisol, thereby maintaining the levels
of fetal ACTH, cortisol, and DHEA-S synthesis. It has
beenproposed that thismechanismmayunderlie the rapid
growth of the fetal adrenal cortex around midgestation
(121, 122). Furthermore, fetal adrenal glucocorticoids
stimulate placental CRHproduction, thereby establishing
a positive feedback circuit in the fetoplacental unit, lead-
ing to constantly increasing CRH, ACTH, and cortisol
concentrations toward late gestation (103).
Taken together, the fetal neuroendocrine system is sub-
ject to complex regulation via negative and positive feed-
back mechanisms.
4. Adaptation of the hpa axis to extrauterine life
Immediately after birth, the fetal zone of the adrenal
cortex degenerates extensively, whereas the zona fascicu-
lata matures within 3 wk (123). Mesiano and Jaffe (102)
argue that despite the dramatic remodeling of the adrenal
cortex, there is no evidence of adrenocortical insufficiency
in term infants during this critical period because adult
cortical zones become functional before birth. Indeed, se-
rum levels of cortisol were shown to gradually increase
after birth in term infants (124). Evenpreterm infants born
between 24 and32wkgestation exhibited a rise in cortisol
concentrations within the first day postpartum, presum-
ably due to the stress of delivery. Thereafter, values de-
creased again up to age 4 wk, but did not fall below con-
centrations observed around birth (125). However, other
investigators showed a rapid decline in ACTH, cortisol,
and cortisone precursors, accompanying the decrease of
DHEA-S, in term and preterm infants immediately after
birth with a nadir approximately 2 months postpartum
(100). Further studies are required to clarify this issue.
It is of note that, compared with term infants, prema-
ture infants are atypical in that theymaintain fetal patterns
of hormonal regulation until remodeled adrenals become
functional.Not surprisingly, therefore, distinct patternsof
hormonal activity, primarily linked to gestational age,
birth weight, and state of health, have been reported in
premature infants (100, 101, 103).
Reports of the actual patterns of cortisol concentra-
tions in premature infants are rather inconsistent. On the
one hand, serum cortisol levels have been shown to be
negatively correlated to gestational age, with infants born
at shorter gestational ages displaying higher cortisol con-
centrationswithin the first year after birth than those born
closer to full term (124, 126). It can be hypothesized that
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the increased cortisol production rate in preterm infants
represents a sustained intrauterine pattern of hormone
production that is characterized by a dramatic rise in cor-
tisol production before parturition, whereas comparably
lower production rates in infants with higher gestational
ages may go along with the adrenal remodeling that takes
place around birth. On the other hand, low birth weight
infants born between 23 and 32wk gestationmeet criteria
for reduced basal endocrine function (127). Preterm in-
fants display significantly increased concentrations of cor-
tisol precursors, including 17-hydroxyprogesterone (17-
OHP) and 11-deoxycortisol, comparedwith term infants,
whereasbasal cortisol values are similar in thepretermand
term groups (128, 129), indicating reduced activity of
some steroidogenic enzymes due to adrenal immaturity.
Furthermore, whereas some authors demonstrated
fairly adequate adrenocortical responses after pharmaco-
logical challenge with CRH in premature infants (130,
131), others observed a decreased adrenal reserve after
CRH challenge (127, 132). In sum, the endocrine patterns
in pretermand term infants aroundbirth have not yet been
fully elucidated and may be subject to a wide range of
influencing factors. As noted above, the ontogeny of GR
in hypothalamus and pituitary have also not yet been
elucidated.
Taken together, hpa axis activity starts early in embry-
onic life, passing through dynamic changes throughout
gestation and the neonatal period up to adult life. Ade-
quate maturation of the hypothalamus, pituitary, adrenal
cortex, and systems involved in the regulation of the hpa
axis serves appropriate ontogeny. Disturbances of this
complex maturational process may thus result in a dys-
functional endocrine system later on, with potential dis-
turbances due to synthetic glucocorticoid activation of
GRs in fetal hypothalamus, pituitary, or structures in-
volved in their regulation, particularly in at-risk fetuses,
being the focus of this review.
III. Methods of the Systematic Review
We conducted the systematic review according to the
guidelines set forth by the Meta-analysis of Observa-
tional Studies in Epidemiology (MOOSE) group for re-
porting of systematic reviews of observational studies
(for the MOOSE checklist, see Supplemental Material
1, published as supplemental data on The Endocrine
Society’s Journals Online web site at http://jcem.
endojournals.org) (133).
Within this systematic review (see Ref. 134 for defini-
tion), we integrated scientific publications describing the
effects of intrauterine exposure to synthetic glucocorti-
coids on fetal, newborn, and infant hpa function in hu-
mans.We applied an explicit and reproducible strategy to
locate, appraise, and select evidence and give directives for
future research. Because we did not review an effect of
treatment on pathology, but rather systematically re-
viewed the evidence for the effect (or lack of effect) of
intrauterine exposure to a class of substances (i.e., glu-
cocorticoids) on physiological indicators of a complex
physiological system (i.e., hpa axis), this resulted in
strongly heterogeneous sources of evidence. Conse-
quently, we did not apply quantitative techniques from
meta-analyses, but nonetheless still systematically inte-
grated the evidence available to date.
A. Criteria for including studies in this review
1. Types of study design
All randomized, controlled studies and quasi-experi-
mental studies (allocation of women to study groups on
the basis of nonrandomized clinically prescribed treat-
ment) comparing the effects of intrauterine exposure to
synthetic glucocorticoids vs. placebo or vs. no treatment
on hpa function were considered for inclusion in this re-
view. Furthermore, studies comparing the effects on hpa
function of different glucocorticoid doses or different time
intervals between treatment and birth or treatment and
sample collection were taken into account. Other study
designs (i.e., case reports and studies assessing the effects
of intrauterine glucocorticoids on hpa activity within
other primary research questions) were also included in
this review, so as to present as complete a picture as pos-
sible of the research conducted in this field. Case reports
were kept where external reference values were applied to
analyze the effects of intrauterine glucocorticoid expo-
sure. As recommended, we used broad inclusion criteria
and then performed analyses relating design features to
outcome (133). This is the first systematic review on this
subject in humans to date.
2. Participants and type of exposure
We included all investigations of the offspring of
womenwhowere treated during pregnancywith any kind
of synthetic glucocorticoid due to any medical condition
and regardlessofother comorbidity.Weaimedat studying
the offspring, regardless of gestational age at birth, birth
weight, and health status, at fetal, neonatal, infant, or
adult life stage. Hence, no restrictions were placed.
3. Outcome measures
Outcomemeasures of interest were those considered to
be directly indicative of hpa axis activity and comprised:
ACTH, cortisol, the cortisol precursors 11-deoxycortisol
and 17-OHP, the cortisol metabolite cortisone, the quan-
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titatively principal steroid hormone of the fetal adrenal
gland dehydroepiandrosterone (DHEA), its sulfated form
DHEA-S, and placental CRH mRNA. These substances
were measured in amniotic fluid, (cord) blood, saliva, or
placental tissue.
B. Search strategy for identification of studies
We searched PubMed from the U.S. National Library
ofMedicine via theweb-based search and retrieval system
provided by the National Center for Biotechnology Infor-
mation, from January 1965 to July 2007, using the web-
browser Firefox.We placed no restrictions on language. A
detailed description of the search strategy is provided in
Supplemental Material 2.
The articles identified by this search in PubMed were
assessed according to the criteria of consideration for this
review outlined above. We also contacted several authors
for unpublished and unrecognized studies on the topic.
There was no further contact with authors. Furthermore,
we hand-searched bibliographies of identified original
publications and evaluated them according to the criteria.
The flowchart of the literature search for studies on the
association between intrauterine exposure to synthetic
glucocorticoids and fetal, newborn, and infant hpa func-
tion is provided in Fig. 1.
C. Methods of the review and study characteristics
1. Selection and coding of the data
Two investigators (M.T. and G.M.) reviewed all arti-
cles independently. If there was ambiguity in selection or
coding, the two investigators discussed this issue and re-
solved disagreements until they reached consensus. We
identified 50 published studies from the last 32 yr thatmet
our inclusion criteria.One of the 50 studies assessed anen-
cephalic fetuses (135). Because anencephalic fetuses do
not have an intact hpa system and rarely survive the first
4 wk after birth (136), we decided to exclude this study
from the review.Hence, 49 studieswere finally included in
the analyses.
The extracted data included the results regarding the
effect of synthetic glucocorticoids on the hpa axis, as well
as study design, number of subjects, type of glucocorticoid
administered, route of administration, details on prepa-
ration, number of administrations and dose, treatment
indication, gestational age at birth, and birth weight. The
extracted data are presented in tables as Supplemental
Materials 3, 4, and 5.
2. Assessment of heterogeneity
Heterogeneity of studies was assessed with regard to
relevant study characteristics, including design, type of
glucocorticoid, treatment indication, measure of hpa ac-
tivity, data collection method, control of potential con-
founders, and sample size. In sum, there was substantial
heterogeneity of the studies in several key aspects. Of the
49 studies, five used experimental and 42 used quasi-ex-
perimental designs, whereas two authors reported on in-
dividual cases exclusively. Apart from the case reports, the
mean number of subjects was 108 (median, 61; range, 6 to
710). The main glucocorticoid agents studied were beta-
methasone (in 31 studies) and dexamethasone (in 17 stud-
ies). These were primarily administered in cases at risk of
preterm delivery to induce fetal lung maturation using an
im route of administration. However, other glucocorti-
coid agents (e.g., prednisolone) and other treatment indi-
cations (e.g., asthma) were also studied (see Supplemental
Materials 3, 4, and 5).
3. Description of method to integrate the study results
As previously suggested, in case of substantial hetero-
geneity across studies, pooled estimates shouldnotbepub-
lished (137). Although several procedures exist that allow
for quantitative synthesis despite heterogeneity, we re-
frained from applying them because in our case their ca-
veats (138) would have outweighed the advantage of pro-
FIG 1. Flowchart of the literature search for studies on the association
between intrauterine exposure to synthetic glucocorticoids and fetal,
newborn, and infant hpa axis function.
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ducing summary scores with questionable explanatory
power. Instead, we separately summarized the results ac-
cording to: 1) several aspects and ontogenetic time points
of hpa function (namelybasal function in fetus, basal func-
tion in neonate/infant/adult, hpa reaction to pharmaco-
logical/physiological challenge, and hpa reaction to
psychological challenge); 2) amount of glucocorticoid
administered; and 3) time interval between treatment and
sample collection. To address the problems of potential
bias due to restrictive study inclusion as well as heteroge-
neity, we used broad inclusion criteria for studies but then
grouped the findings according to study and outcome
features.
4. Assessment of study quality, including control
for confounding
We individually assessed relevant methodological as-
pects in separate study quality indicators and explored
their influence on the results (139). The quality indicators
included randomization, comparability of treatment and
control group or adequate control for confounding, ho-
mogeneity of type of treatment/treatment indication, and
sample size. Randomization qualitywas scored as: no ran-
domization (0), partial randomization (1), or complete
randomization (2). Comparability of treatment and con-
trol group or adequate control for confounding (e.g., in-
clusion as covariate), with respect to indication, gesta-
tional age at birth (evaluated as comparable, if difference
of group means 1 wk), and birth weight (evaluated as
comparable, if difference of group means 100 g), was
scored as: comparable/controlled in one or no parameter
(0), comparable/controlled in two parameters (1), or com-
parable/controlled in all three parameters (2). Homoge-
neity of type of treatment and treatment indication was
scored as: both nonhomogenous (0), only one homoge-
nous (1), or both homogenous (2). Sample size was scored
as number of subjects with exposure to glucocorticoids:
fewer than 25 (0), 25–50 (1), ormore than 50 (2).We took
sample size as a study quality criterion into account, in-
stead of calculating post hoc power analyses because the
latter procedure has been strongly criticized (140, 141),
and, moreover, the determination of appropriate and
comparable effect sizeswouldhavebeenmostly unfeasible
due to large heterogeneity of design and statistical analy-
ses, and, in some of the earlier publications, lack of report
of detailed statistics. The results of the quality scores are
depicted in Table 1. The studies differed substantially in
their quality according to all quality indicators. We there-
fore stratified the findings according to indicators of study
quality (seeRef. 133). This allowedus to take into account
the study characteristics that may have influenced the
study results, especially studydesign, heterogeneitywithin
studies, and sample size.
IV. Results
The description and integration of study results are di-
vided into five sections: 1) the effects of synthetic glu-
cocorticoids on basal hpa function in the fetus; 2) the ef-
fects of synthetic glucocorticoids on basal neonate, infant,
and adult hpa function—we define “basal hpa function”
as hpa function without systematic pharmacological or
psychological stimulation as opposed to pharmacologi-
cally or psychologically stimulated hpa function (142); 3)
the effects of synthetic glucocorticoids on neonate and
infant hpa function after pharmacological or physiologi-
cal challenge; 4) the effects of synthetic glucocorticoids on
neonate and infant hpa function after psychological chal-
lenge; and 5) the relationships between the amount of glu-
cocorticoid administered, or the time interval between
treatment and sample collection on the one hand, and basal
and reactive hpa function in the fetus, neonate, and
infant on the other hand. Supplemental Materials 3, 4,
and 5 summarize the major findings of the studies.
A. Effects of intrauterine exposure to synthetic
glucocorticoids on basal hpa function
1. Effects in the fetus
A number of studies assessed basal hpa function in the
fetoplacental unit by measuring markers of fetal hpa ac-
tivity in cord blood and amniotic fluid during gestation
and at birth. Compared with unexposed healthy fetuses,
cortisol concentrations are significantly lower in other-
wise healthy fetuses exposed to synthetic glucocorticoids
in utero, with values decreasing to only 10% of the con-
trols (59, 65, 68, 143–155). Likewise, fetuses with con-
genital diaphragmatic hernia (CDH) exposed to synthetic
glucocorticoids in utero exhibit significantly lower plasma
cortisol concentrations than both healthy fetuses and
CDH fetuses not exposed to betamethasone in utero
(156). In fetuses of asthmatic mothers who refrain from
taking synthetic glucocorticoids during pregnancy, corti-
sol concentrations are significantly increased compared
with fetuses of healthy controls; in fetuses of treated asth-
matic mothers, a dose-dependent restoration of cortisol
levels down to control values occurs with increasing glu-
cocorticoid doses (157), suggesting that synthetic glu-
cocorticoids suppress the hpa axis in the fetus. Similarly,
placental CRH mRNA is slightly increased in asthmatic
parturients not treated with synthetic glucocorticoids
compared with controls, whereas treated asthmatic par-
turients exhibit normal levels irrespective of the treatment
dose (157).
Similar to cortisol, ACTH (150, 156), DHEA (156),
and DHEA-S (143, 152) concentrations are reduced in
treated fetuses.
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TABLE 1. Quality indicators of studies that assessed in individuals exposed to synthetic glucocorticoids in utero the
hpa axis function under basal conditions, after pharmacological challenge, and after pain-related stimulation
First author, year (Ref.)
Study quality indicators
Randomizationa
Comparability of treatment
and control groupsb
Homogeneity of type of
treatment and treatment
indicationc
Sample
sized
Basal conditions
Arnold, 1998 (164) 0 0 0 0
Ballard, 1975 (65) 1 1 1 1
Balllard, 1980 (143) 1 0 2 2
Banks, 1999 (200) 0 0 1 2
Dalziel, 2005 (184) 2 2 2 2
Dorr, 1986 (144) 0 0 2 0
Dorr, 1993 (158) 0 0 2 1
Gatelais, 2004 (198) 0 0 2 2
Gennser, 1976 (145) 0 1 2 1
Kajantie, 2003 (68) 0 1 2 2
Kajantie, 2004 (147) 0 1 2 2
Karlsson, 2000 (166) 0 1 2 2
Kauppila, 1978 (148) 0 0 2 1
Kavelaars, 1999 (149) 0 0 1 1
Manabe, 2005 (159) 0 0 0 0
Marinoni, 1998 (150) 0 1 2 0
Murphy, 2002 (157) 0 1 1 2
Murphy, 2003 (69) 0 1 1 2
Ng, 1997 (131) 0 1 1 0
Ng, 2001 (199) 0 0 2 2
Nordenstrom, 2001 (181) 0 0 0 2
Nykänen, 2007 (160) 0 0 1 1
Ohrlander, 1975 (151) 1 1 2 0
Osathanondh, 1977 (59) 2 0 2 0
Paddock, 2004 (156) 0 0 2 0
Parker, 1996 (152) 0 0 2 2
Shulman, 2001 (177) 0 0 0 2
Sippell, 1980 (153) 0 0 2 0
Sybulski, 1977 (154) 0 0 2 1
Terrone, 1997 (169) 0 2 2 2
Wittekind, 1993 (168) 0 0 2 0
After pharmacological challenge
Battin, 2007 (170) 1 2 2 2
Bradley, 1994 (165) 0 0 0 0
Kairalla, 1992 (146) 0 0 2 0
Ng, 1997 (174) 0 0 2 1
Ng, 1999 (172) 0 0 2 0
Ng, 2002 (167) 0 1 2 2
Noguchi, 1978 (185) 0 1 1 0
Ohrlander, 1977 (175) 0 0 0 1
Sandesh Kiran, 2007 (176) 0 2 2 2
Teramo, 1980 (155) 2 0 2 0
Terrone, 1999 (186) 0 0 1 0
Wilson, 1988 (178) 0 0 1 0
After pain-related stimulation
Ashwood, 2006 (186) 2 1 2 1
Davis, 2004 (171) 0 0 2 0
Davis, 2006 (188) 0 1 2 0
Glover, 2005 (180) 0 0 0 1
Miller, 2004 (179) 0 0 1 0
a Randomization scores: no randomization, 0; partial randomization, 1; complete randomization, 2.
b Scores for comparability of treatment and control group or adequate control for confounding regarding treatment indication, gestational age at birth (evaluated as
comparable, if difference of group means 1 wk); birth weight (evaluated as comparable, if difference of group means 100 g): comparable/controlled in one or no
parameter, 0; comparable/controlled in two parameters, 1; comparable/controlled in all three parameters, 2; not reported is coded as not comparable.
c Homogeneity of type of treatment and treatment indication scores: both nonhomogenous, 0; only one homogenous, 1; both homogenous, 2; not reported is coded
as not homogenous.
d Sample size scores: number of offspring with exposure to glucocorticoids  25, 0; 25–50, 1; 50, 2.
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Levels of the cortisol metabolite cortisone are reduced
by 50% in umbilical venous blood of fetuses exposed to
synthetic glucocorticoids (144, 153). Furthermore, the
cortisol precursor 11-deoxycortisol is reduced in cord
blood (144). However, in midpregnancy amniotic fluid,
both cortisone and 11-deoxycortisol concentrations are
similar in treated and untreated CAH pregnancies as well
as in treated and untreated pregnancies without patho-
logical outcomes (158). Results for amniotic fluid and
cord blood 17-OHP, the precursor of 11-deoxycortisol,
are inconsistent; 17-OHP is either decreased (153) or un-
changed (144) in cord blood and is nonsignificantly re-
duced in amniotic fluid (144, 153, 158).
In sum, 18 of 22 studies demonstrated, in terms of at
least one marker, that basal hpa function as measured in
amniotic fluid and cord blood is reduced in fetuses ex-
posed to synthetic glucocorticoids in utero, whereas no
study observed the opposite effect. However, four groups
reportno significant effectsof synthetic glucocorticoidson
fetal hpa axis (69, 158–160).
Restricting the synthesis to studies with either random-
ized study assignment (study quality indicator “random-
ization”1) or comparability between exposed and con-
trols (study quality indicator “comparability”  2)
revealed that all five identified studies (59, 65, 143, 151,
155) demonstrate that basal hpa function is reduced in
fetuses exposed to synthetic glucocorticoids in utero.
Restricting the synthesis to studieswithhomogeneity of
type of treatment and treatment indication (study quality
indicator “homogeneity”  2) revealed that 15 of the 16
identified studies (59,68,143–148,150–156)did, butone
(158) did not, demonstrate that basal hpa function is re-
duced in fetuses exposed to synthetic glucocorticoids in
utero.
Restricting the synthesis to studies with large sample
size (study quality indicator “sample size”  2) revealed
that five of the six identified studies (68, 143, 147, 152,
157) did, but one (69) did not, demonstrate that basal hpa
function is reduced in fetuses exposed to synthetic glu-
cocorticoids in utero.
In sum, sensitivity analysis revealed that the finding of
a reduced basal hpa function in glucocorticoid-exposed
fetuses is strongly consistent in studieswith higher quality.
Secretagogues andmetabolites of fetal hpa axis, includ-
ing cortisol, ACTH, DHEA, DHEA-S, 11-deoxycortisol,
17-OHP,andcortisone, havebeen shown tobe suppressed
in amniotic fluid and cord blood of glucocorticoid-ex-
posed fetuses. This observation indicates either an inhibi-
tion of the entire fetal hpa axis or an inhibition at a higher
hpa axis level rather than a reduced function of particular
zones or enzyme systems in the adrenal cortex, although
not all groups have confirmed suppression of cortisol, 11-
deoxycortisol, 17-OHP, and cortisone. Discrepant find-
ings between studies that observed hpa axis suppression
and those that did not may be rooted in varying study
quality and characteristics, including treatment indica-
tion, agent, or dose, as will be discussed in Sections IV.C,
IV.D, and V.B. Interestingly, concentrations of cortisone
and 11-deoxycortisol are reduced in cord blood, whereas
they are unchanged in midpregnancy amniotic fluid, sug-
gesting that cortisone and 11-deoxycortisol reduction as a
consequenceof exposure to synthetic glucocorticoids does
not occur as early as midgestation and that it takes some
timeuntil synthetic glucocorticoids take effect on fetal hpa
axis. It should be noted that most authors have studied
cortisol as “the” marker of fetal hpa axis function, al-
though DHEA is the major adrenal steroid hormone pro-
duced in the fetus that is under pituitary control.
The slightly decreasedplacentalCRHmRNAin treated
compared with untreated asthma patients may suggest
that synthetic glucocorticoids, besides suppressing fetal
hpa axis, directly impact on placental CRH production.
Against the background of placental CRH being involved
in a positive feedback circuit with the fetal hpa axis (see
Section II.D), the observed reduced placental CRH
mRNA in treated comparedwith untreated asthmatic par-
turients may also be either a direct cause or a consequence
of reduced fetal hpa axis activity.
There are some methodological differences between
studies, with some reporting on mixed cord blood and
others analyzing arterial and/or venous blood separately.
However, glucocorticoid concentrations in arterial and
venous cord blood have been shown to be largely equal
(144, 145), indicating that the umbilical vein, although
carrying bloodof placental origin, also accurately predicts
hormonal activity in the fetus. Furthermore, it cannot be
excluded that endocrine markers, as measured in cord
blood or amniotic fluid, are of maternal origin at least in
part. However, there is evidence that cortisol concentra-
tions in amniotic fluid are closely associated with the level
of cortisol in fetal plasma (145). Finally, stress duringbirth
itself has recently been shown to alter cortisol concentra-
tions in cord blood (161–163). Therefore, it cannot be
excluded that in the studies reviewed, indicators of hpa
function in cord blood have been influenced by stress of
delivery and do not represent the fetal environment ex-
clusively. To further evaluate the impact of intrauterine
glucocorticoid exposure on the endocrine system, hpa
function needs to be determined in a setting that is inde-
pendent from delivery.
2. Effects in the neonate and infant
We identified 21 studies that have investigated the im-
pact of intrauterine exposure to synthetic glucocorticoids
on basal hpa function at some age between the first day
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and 1 yr postpartum.Most of these studies focused on the
first postnatal days and weeks. One third of the studies
report that in treated infants, plasma cortisol concentra-
tions are reduced relative to controls during the first post-
natal days and weeks (153, 164–168). In one report, this
phenomenon is at least evident in some but not all of the
neonates studied (169). In addition, some of these same
studiesobserved that cortisol concentrations subsequently
increase to control levels by 2 wk postpartum at the latest
(153, 166–168). Slightly more than 60% of the studies
report unchanged basal cortisol concentrations during the
first days and weeks postpartum (144, 146, 160, 170–
178) or during the first 4 months of life (179) after
intrauterine exposure to synthetic glucocorticoids. Re-
cently, one group has reported a significant positive
association between intrauterine exposure to synthetic
glucocorticoids and basal cortisol concentrations at 4
months of age (180).
Other secretagogues of hpa axis, namely ACTH (167,
168, 170), 17-OHP(144, 153, 181), and11-deoxycortisol
(170) have been shown to be in the normal range, at least
within the first week postpartum, in infants exposed to
synthetic glucocorticoids in utero.
It is of note that one study assessed the effects of intra-
uterine glucocorticoids on hpa function separately in pre-
termand term infants eachwith a respective control group
(148). Interestingly, the effects are different inpretermand
term infants. In preterm neonates, glucocorticoid expo-
sure is associated with increased cortisol concentrations
on postnatal d 6. In term neonates, intrauterine exposure
to glucocorticoids is associated with significantly lower
cortisol concentrations at 30 and 60 min after delivery
relative to controls, indicating a decreased stressor re-
sponse to birth. The observation that gestational age in-
fluences the effects of intrauterine exposure to synthetic
glucocorticoids on hpa function is discussed in detail in
Section V.B.
In sum, one third of the studies show that intrauterine
exposure to synthetic glucocorticoids results in reduced
cortisol concentrations in the neonate and infant, one
study demonstrates increased basal cortisol levels, and
more than half of the studies report no effect.
Restricting the synthesis to studies with either random-
ized study assignment or comparability between exposed
and controls revealed that one (169) of these studies found
some indication that intrauterine exposure to synthetic
glucocorticoids results in reduced cortisol concentrations
in the neonate and infant during the first days and weeks
postpartum, whereas two studies did not (170, 176).
Restricting the synthesis to studieswithhomogeneity of
type of treatment and treatment indication revealed that
five of 13 identified studies (153, 166–169) report that
intrauterine exposure to synthetic glucocorticoids results
in reduced cortisol concentrations in the neonate and in-
fant during the first days postpartum, whereas seven do
not observe significant effects (144, 146, 170–172, 174,
176), and one study (148) shows mixed results.
Restricting the synthesis to studies with large sample
size revealed that three (166, 167, 169) studies show some
indication that intrauterine exposure to synthetic glu-
cocorticoids results in reduced hpa activity in the neonate
and infant during the first days postpartum, whereas four
studies do not (170, 176, 177, 181).
In sum, sensitivity analysis revealed a picture similar to
that of the synthesis including all available studies. More
than half of the results from studies with higher quality
show that intrauterine exposure to synthetic glucocorti-
coids is not associated with changes in hpa activity in the
neonate and infant, whereas roughly one third of the stud-
ies demonstrate reduced basal cortisol levels, but no study
shows increased basal values.
a. Pulsatile cortisol secretion.One study specifically investi-
gated the pulsatile characteristics of cortisol secretion in
infants antenatally exposed to glucocorticoids (164). The
median amplitude of cortisol secretory bursts, as mea-
sured at 15-min intervals for 6 h, is significantly lower in
treated infants, whereas the number of secretory bursts,
interpulse interval, cortisol secretory burst half-duration,
mass of cortisol secreted per burst, production rate, and
elimination half-life are comparable to unexposed sub-
jects (164). In studies in healthy adults, it is well docu-
mented that cortisol and ACTH secretion are regulated
mainly by amplitude rather than other characteristics of
the secretory bursts (182, 183), indicating that the ob-
served reduction of cortisol amplitude secretory bursts is
important. However, results should be interpreted with
caution, according to study quality indicators.
b. Time course of recovery of basal adrenal activity. To assess
the development of basal hpa activitywithin the first post-
natal weeks in infants prenatally exposed to glucocorti-
coids, a numberof studies havemeasured endocrinemark-
ers repeatedly at different points in time. Some of these
started with assessment in cord blood at birth, whereas
others began in the first postnatal hours or days.
Remarkably, the exact timing of adrenal recovery var-
ies considerably between studies. One group reports de-
creased glucocorticoid concentrations at birth, followed
by normalization in cortisol and 11-deoxycortisol levels
after 2 h. During the further postnatal course, the levels of
the treated group are not different from control levels
(144).Moreover, 17-OHPvalues arewithin normal range
by 2 h postpartum, although they are reduced in cord
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blood (153). Further results show that betamethasone-
induced suppression of adrenal function, as evidenced in
the umbilical vein immediately after birth, is no longer
demonstrable at 24 h of age (155), at d 5 (146), or at d 14
postpartum (153). Other authors measured reduced cor-
tisol concentrations in prenatally treated infants at 12 h
(166) or 1 wk (167, 168) after birth, reaching normal
levels again at 2 d and 2 wk postpartum, respectively.
Finally, one group showed that cortisone levels recover 9d
postpartum (153).
Taken together, there are two main findings: 1) the
overall pattern of time course of basal hpa function is
roughly comparable across studies, consisting mostly of a
short period of reduced activity, which is then followed by
a recovery to normal levels; and 2) most of the studies
found restored hpa function by 2 wk postpartum.
However, the question remains as towhether basal hpa
axis activity remains normal beyond the first 2 wk of life
because infants were followed beyond that time in four
studies only (168, 177, 179, 180). In three of these four
studies, normal adrenal function was observed beyond 2
wk of life, indicating that recovery may be completed by
that time (168, 177, 179). Restoration may be achieved
through the dramatic remodeling of the adrenal cortex
within the first days postpartum (see Section II.D), which
probably compensates for early dysregulation. In the
fourth study, specifically, a significant positive association
between prenatal glucocorticoid exposure and basal cor-
tisol concentrationsat4monthsof agewas reported (180).
The latter finding provides isolated evidence for a switch
from reduced hpa function in the first postnatal weeks to
an overactive endocrine system later on. This issue is dis-
cussed in detail in Section V.E.
Mild, temporary suppressionof cortisol concentrations
by antenatal glucocorticoid exposure does not appear to
co-occurwith altered levels of 11-deoxycortisol (170), 17-
OHP (144, 153, 181) or ACTH (167, 168, 170) concen-
trations within the first week postpartum. These results
are different from the findings in cord blood described
above. Taken together, these observations indicate that
pituitary function and certain steps in adrenal steroido-
genesis might recover earlier than cortisol synthesis.
The following investigation gives reason tohypothesize
that intrauterine glucocorticoid exposure leads to fairly
complex endocrine dynamics that cannot be reduced to a
scheme delineating a simple time course of suppression of
fetal and newborn hpa axis that is followed by sustained
recovery. Rather, these complex endocrine patterns seem
to persist beyond the first weeks of life. Miller et al. (179)
reported on a specific endocrine pattern that they detected
only in infants exposed to prednisolone in utero, but not
in controls. They demonstrated a trend toward an inverse
relationship between basal cortisol concentrations at 2
months and basal cortisol levels at 4 months, those with
increased basal cortisol concentrations at 2months hav-
ing decreased basal cortisol concentrations at 4 months
and vice versa. This phenomenon describes an unstable
endocrine system that is not characterized by either
strict hypo- or hyperactivity as a basic principle and
gives reason to reconsider rigid, universal disordermod-
els of hypo- or hyperfunction. This issue should be ad-
dressed further.
In sum, a number of studies indicate that in glucocor-
ticoid-treated infants, recoveryof cortisol suppression, the
physiological basis of which may be a reduced amplitude
of cortisol secretory bursts, is completed by 2 wk post-
partum, whereas there is inconclusive evidence for a
chronic effect on hpa axis dysregulation beyond that time.
3. Effects in the adult
To date, only a single study with high quality followed
individuals thatwere exposed to synthetic glucocorticoids
inutero intoadulthood (184).At age30,meanearlymorn-
ing cortisol concentrations show a tendency to be in-
creased by 7% in the betamethasone group when com-
pared with the placebo group. This average increase was
abolished after adjusting for sex, trial type, birth weight,
gestational age at birth, body mass index, and oral con-
traceptive use, although it can be speculated that this ad-
justment eliminated not only confounding but also medi-
ating factors. In linewith the findingsbyGlover et al. (180)
described above, this finding tentatively suggests a switch
from reduced hpa function to increased activity of the
endocrine stress system in the long term.
B. Effects of intrauterine exposure to synthetic
glucocorticoids on hpa reactivity
Reactivity of neonatal and infant hpa axis has been
evaluated by means of pharmacological challenge (146,
155, 165, 167, 170, 172, 174–176, 178, 185, 186) after
physiological burden (143), as well as after painful stres-
sors (171, 179, 180, 187, 188). Basal hpa activity does not
reflect hpa reactivity to stimulation (142). Therefore, in
the following sections,we separately present the results on
the associations of intrauterine exposure to synthetic glu-
cocorticoids and hpa reactivity.
1. Pharmacological challenge
Eleven studies evaluated the axis’ ability to react to one of
the following pharmacological challenges after being ex-
posed to synthetic glucocorticoids inutero:ACTHorACTH
agonists (155, 165, 175, 176, 178, 185, 186), metyrapone
(146, 170), or human CRH (hCRH) (167, 172, 174).
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a. ACTH challenge. Seven studies tested adrenal function in
newborns exposed to synthetic glucocorticoids in uteroby
stimulation via ACTH or ACTH agonists within the first
2months of life. Infants prenatally exposed to betametha-
sone show an increase in serum cortisol concentrations
after stimulation by ACTH within the first 3 d of life,
indicating only, given that there was no control group
included in these studies, that they are actually able to
mount an adrenocortical response to ACTH (165, 186).
Cortisol responses to ACTH administration are not sig-
nificantly different in glucocorticoid-treated and un-
treated infants on the first and third days postpartum,
although the average increment in cortisol concentration
is somewhat lower in the glucocorticoid treatment group
(155, 176). Likewise, four glucocorticoid-treated infants
studiedwithin another primary researchquestionhad cor-
tisol and DHEA-S responses comparable to those of un-
treated infants after ACTH stimulation 1 and 4 wk post-
partum (185). Finally, intrauterine exposure to synthetic
glucocorticoids has no effect onACTHstimulated cortisol
increases in a highly selective sample of newborns who
were also postnatally treated with dexamethasone due to
bronchopulmonary dysplasia, when studied up to 6 wk
after birth (178).
In sum, within the first 6 wk postpartum there is no
evidence for alteredadrenocortical reactivity to a standard
dose of ACTH after exposure to synthetic glucocorticoids
in utero.
Terrone et al. (186) andTeramo et al. (155)used similar
test protocols, administering synthetic ACTH at a stan-
darddoseof 0.25mg/1.73m2anddrawingpoststress sam-
ples after 120 min. Using different protocols with ACTH
doses of 0.015 mg/kg and sample collection as soon as 60
min after injection (175) or ACTH doses of 0.1 g/kg
(176), neither of the latter groups found differences in
cortisol responses between treated and untreated infants
either.
Terrone et al. (186) considered amean cortisol increase
of 7.62g/100ml to be indicative of normal adrenal func-
tion in infants prenatally exposed to steroids. However,
the latter investigation did not include a control group.
Interestingly, cortisol rises in treated anduntreated infants
reportedbyothergroupsrangebetween20and50g/100ml
(155, 165), indicating that adrenal function in the former
investigation might have been slightly suppressed.
Studies consistently demonstrating a normal cortisol
response after the ACTH stimulation test in infants ex-
posed to synthetic glucocorticoids in utero are to some
extent counterintuitive given the observations of sup-
pressed basal hpa function after intrauterine exposure to
synthetic glucocorticoids (see Section IV.A). Taking both
findings together, itmaybe speculated that the level of hpa
axis inhibition leading to low basal cortisol values is most
likely located at the level of the hypothalamus or pituitary
gland rather than at the adrenocortical level.
b. Metyrapone challenge. To study the integrity of the pitu-
itary and the adrenocortex, 2dafter birthmetyraponewas
administered to infants exposed to single or repeated be-
tamethasone courses in utero, and blood ACTH, cortisol,
and 11-deoxycortisol concentrations were measured 3 h
thereafter (170). Although cortisol levels fall in response
to metyrapone, this response is not different between the
single and repeated course groups. Furthermore, groups
do not differ in ACTH responses and 11-deoxycortisol
concentrations measured 3 h after metyrapone adminis-
tration. Another author performed a metyrapone test on
a set of betamethasone-treated triplets on d 5 after birth
(146).Only one of the infants shows the predicted cortisol
decrease from pre-metyrapone levels, indicating that in-
hibition of the enzyme 11- hydroxylase that converts
11-deoxycortisol to cortisol was not complete. However,
plasma 11-deoxycortisol levels rise 10- to 20-fold to ex-
pected values of around 3 g/dl in all infants after oral
stimulation with metyrapone.
Results from the studyusingmetyrapone stimulation1)
confirm findings from studies using the ACTH test, both
indicating an intact adrenocortical activity in infants ex-
posed to synthetic glucocorticoids in utero; and 2) dem-
onstrate an uncompromised pituitary reserve and feed-
back because the metyrapone test has been shown to be a
reliable indexof secondary adrenal insufficiency (189). To
confirm observations of these reports, more controlled
studies using the metyrapone test and involving a larger
sample size are needed.
c. CRH challenge. In a series of studies, Ng et al. (167, 172,
174) used the hCRH stimulation test to assess pituitary
and adrenal function ond7 and14 after birth. In their first
study in 1997 they found no suppressed ACTHor cortisol
concentrations in preterm, very low birth weight infants
prenatally exposed to one, two, or more doses of dexa-
methasone, either at baseline or at 15, 30, and60min after
hCRH stimulation (174). In a later study, the same group
reported lower baseline and 15 and 60 min post-hCRH
stimulation levels of cortisol in infants prenatally ex-
posed to one or two, but not in infants exposed to more
than two, dexamethasone doses, when compared with
controls at d 7 (167). However, net cortisol increases
were comparable in all groups. Furthermore, no signif-
icant differences in baseline and post-hCRH stimula-
tion ACTH concentrations were observed among the
groups on d 7 and 14 (167).
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To address the question of whether multiple courses of
antenatal dexamethasonewould suppresshpaactivity,Ng
et al. (172) performed another prospective study investi-
gating the effect of eight ormore doses of dexamethasone.
The number of doses ranged between eight and eighteen,
with a mean of 11.6 doses. In the absence of an ideal
control group, results were compared with previous find-
ings from untreated infants who had their hpa function
assessed in a study applying a comparable protocol (174).
The serum cortisol concentrations 60 min after hCRH
stimulation on day 7, specifically, are significantly lower
in the treatment group than in the nontreatment group,
indicating a mildly reduced adrenal reactivity. In sum, in
one of three studies, intrauterine exposure to dexameth-
asone is associated with a mildly suppressed cortisol re-
sponse after stimulation by hCRHond7 postpartum, and
this effect disappears by 2 wk after birth. None of the
studies observes a reduced ACTH response after stimula-
tion by hCRH in treated infants.
Similar to recovery of basal hpa function (see Section
IV.A.2), the mildly suppressed cortisol response after
stimulation by hCRH is no longer observed after 2 wk
postpartum (167), supporting the hypothesis of tempo-
rally restricted cortisol suppression in infants exposed to
synthetic glucocorticoids in utero.
The finding of a reduced cortisol response in infants
prenatally exposed to a mean number of 11.6 dexameth-
asone doses (172) is different from that reported by the
same authors in 2002 when they demonstrated overall
suppressive effects before as well as after hCRH admin-
istration only in infants exposed to less than three doses of
dexamethasone in utero (167). The influence of the
amount of synthetic glucocorticoids administered is dis-
cussed in Section IV.C.
There is only weak evidence for suppressed cortisol
response after hCRH administration in dexamethasone-ex-
posed infants. Moreover, no significant influence of dexa-
methasone exposure on post-hCRH ACTH concentrations
has been reported.
It is of note that a single group, using comparable study
protocols, conducted all studies applying the hCRH test.
More studies are needed to test the reproducibility of these
findings.
In conclusion, pharmacological stimulation does not
reveal suppression of hpa function, except for weak evi-
dence of mild inhibition of the cortisol response after
hCRH administration 7 d postpartum.
Restricting the synthesis to studies with either random-
ized study assignment or comparability between exposed
and controls revealed that all three identified studies (155,
170, 176) show no association between intrauterine ex-
posure to synthetic glucocorticoids and hpa reactivity to
pharmacological stimulation.
Restricting the synthesis to studieswithhomogeneity of
type of treatment and treatment indication revealed that
five (146, 155, 170, 174, 176) of the seven identified stud-
ies show no association between intrauterine exposure
to synthetic glucocorticoids and hpa reactivity to phar-
macological stimulation, whereas two studies report in-
dications of a slightly reduced hpa reactivity to hCRH
(167, 172).
Restricting the synthesis to studies with large sample
size revealed that two of the identified studies (170, 176)
show no association between intrauterine exposure to
synthetic glucocorticoids and pituitary-adrenal reactiv-
ity to pharmacological stimulation, whereas one study
(167) reports indication of slightly reduced hpa reac-
tivity to hCRH.
In sum, sensitivity analysis revealed a picture similar to
that of the synthesis of all available studies: in studies with
higher quality, pharmacological stimulation does not re-
veal suppression of hpa function except forweak evidence
of mild inhibition of the cortisol response after hCRH
administration.
2. Respiratory stress
To evaluate the responsiveness of hpa axis to physio-
logical stressors in infants prenatally treated with beta-
methasone, one studywith high quality determined serum
cortisol levels in infants who were stressed by either in-
trapartum asphyxia or RDS, both clinically highly rele-
vant stressors (143). Among 27 betamethasone-treated
premature infants with significantly lower baseline corti-
sol concentrations at birth compared with untreated in-
fants, cortisol increased in all infants except one in re-
sponse to the stress of disease. Increases observed within
the first 2 h in asphyxiated and within the first 2 d in RDS
infants are not significantly different between treated and
untreated infants, suggesting an intact endocrine reactiv-
ity to physiological stress in the form of respiratory dis-
turbances in infants exposed to synthetic glucocorticoids
in utero.
3. Pain and discomfort
Five very recent studies examined hpa reactivity after
moderate painbypinprickor after discomfort triggeredby
a medical examination or intervention in newborns ex-
posed to glucocorticoid medication in utero (171, 179,
180, 187, 188). More precisely, the authors used blood
sampling by heel prick (171, 187, 188), a physical exam
(171), or nasopharyngeal suction via endotracheal tube
(187) within the first week of life; blood sampling by heel
prick 4 to 6wk after birth (188); or immunization at 2 and
4 (179) or at 4 and 12 (180) months of age as stressors.
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In two studies, Davis et al. (171, 188) demonstrate that
a single course of betamethasone, as opposed to no pre-
natal glucocorticoid treatment, results in a blunted sali-
vary cortisol response to the heel prick in newbornswithin
the first postnatal week. Moreover, on d 3 after birth, the
salivary cortisol response to either the heel prick or naso-
pharyngeal suction is lower in infants exposed to repeat
courses of glucocorticoids compared with those treated
with a single course (187). The suppressive effect of pre-
natal glucocorticoid treatment on the hpa axis response to
pain-related stress can still be observed 4 to 6 wk after
birth (188). Furthermore, antenatal glucocorticoid treat-
ment has been linked to decreased hpa axis reactivity to
vaccination at 4 months postpartum (180). This associa-
tion is no longer apparent 12months postpartum (180). In
contrast to the aforementioned findings,Miller et al. (179)
report that the hpa axis responses to vaccination at 2 and
4 months after birth are comparable in glucocorticoid-
exposed and unexposed infants.
In sum, four of five studies reported reduced pain-re-
lated hpa axis reactivity in neonates and infants exposed
to glucocorticoids in utero. Results are, however, incon-
sistent as to the sustainability of this reduction, with un-
compromised hpa function being apparent between 2 and
12 months postpartum.
Restricting the synthesis to studies with either random-
ized study assignment or comparability between exposed
and controls revealed that the remaining study (187)
shows reducedpain-relatedhpaaxis reactivity inoffspring
exposed to glucocorticoids in utero.
Restricting the synthesis to studieswithhomogeneity of
type of treatment and treatment indication revealed that
all three identified studies (171, 187, 188) show reduced
pain-related hpa axis reactivity in offspring exposed to
glucocorticoids in utero.
None of the identified studies had a large sample size.
In sum, sensitivity analysis, with regard to randomiza-
tion and homogeneity, revealed a consistent picture: stud-
ieswith higher quality show reduced pain-related hpa axis
reactivity in offspring exposed to glucocorticoids in utero.
a. Associationwith basal values and time course of suppression
and recovery.The observation that the hpa axis response to
pain-related stress is decreased in treated infants within
the first postnatal week is in line with those studies that
reported reduced basal hpa function shortly after birth
(see Section IV.A.1), documenting a reduction of hpa axis
activity that is not restricted to basal function but also
appears after painful stimulation immediately after birth.
The ability tomount a cortisol response to pain-related
stress is impaired even beyond the first postnatal days and
can still be observed 4 months after birth. As described
above (Section IV.A.1), at this stage of development it
appears that basal hpa axis activity has returned to control
levels. Taken together, the evidence suggests that there are
two time frames of endocrine hypofunction. Within the
first 2 wk of life, hpa axis activity can be suppressed in
terms of basal levels as well as in response to painful chal-
lenge. Thereafter, reduction of endocrine function seems
to be restricted to painful experiences up to 4 months of
age. Interestingly, a persisting inhibition of endocrine re-
activity to pain-related stress along with normalized basal
values, as hasbeendetected in glucocorticoid-treatednew-
borns in the study by Davis et al. (171), has previously
been demonstrated in remitted depressed patients (190).
One might hypothesize that this endocrine pattern repre-
sents a (lasting) vulnerability for a dysregulated stress re-
activity that may be linked to pathology, as has been
shown in the depressed patients. The pattern might go
back to an abiding depleted capacity of the adrenals,
which especially takes effect under an increased hormonal
challenge. Alternatively, this pattern might hint to an in-
creased feedback sensitivity, which becomes especially
pronounced in challenging situations.
Findings from several studies provide evidence for the
age of recovery from glucocorticoid-induced suppression
of hpa axis reactivity to pain-related stress. Glover et al.
(180) demonstrate uncompromised hpa reactivity to a
painful stressor in infants antenatally exposed to glu-
cocorticoids when they are 12 months of age. Another
group reports appropriate hpa axis responses to pain-re-
lated stress in treated infants as early as 2 and 4 months
after birth (179). These findings indicate that endocrine
reactivity to a painful challenge recovers during the first
year of life but occurs after recovery of basal hpa function.
The exact timing of recovery and the factors that influence
this process both need further study because the recovery
and its timing may be important in terms of disease
vulnerability.
There is a putative limitation to the comparison of find-
ings from studies focusing on basal vs. reactive hpa func-
tion.Although the lattermeasured cortisol concentrations
exclusively in saliva, the former predominantly assessed
hormone levels in blood. However, high correlations be-
tween salivary and serum/plasma concentrations of cor-
tisol have been reported in different populations, includ-
ing newborns and children (191).
Taken together, there is initial evidence that blunted
basal hpa function and blunted hpa axis reactivity to pain-
related stress decouple after the first 2 wk of life, with the
former recovering and the latter exhibiting a persisting
suppression up to age 4 months.
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b. Behavior andheart rate. Interestingly, although endocrine
reactivity to the heel prick is blunted in infants prenatally
treated with glucocorticoids when compared with con-
trols, the increase of behavioral distress after the challenge
is comparable between the two groups, and heart rate
response is actually elevated in the betamethasone group
during the first postnatal week as well as 4 to 6 wk post-
partum (171, 188). This indicates that the treated new-
borns are able to 1) perceive the situation as stressful, and
2) react to the stressful situation in terms of arousal, sug-
gesting that antenatal glucocorticoid exposure selectively
inhibits hpa function but not other aspects of the stress
response. In conclusion, intrauterine exposure to synthetic
glucocorticoids seems to selectively inhibit hpa axis reac-
tivity but not other components of the stress response.
c. Evaluation of stressors. The methods used to assess stim-
ulated hpa activity provide a valid indication of the axis’
normal biological capacity in response to physiologically
relevant pain-related stressors such as heel prick and vac-
cination. These procedures have recently been shown to
result in significant activation of the hpa axis in newborns
(e.g., Refs. 192–194). However, neither prenatally glu-
cocorticoid-exposed nor prenatally untreated infants dis-
play cortisol increases in response to a physical exam
(171). The authors argue that infantsmay habituate tomul-
tiple examsonadaily basis. In support of this interpretation,
all infants additionally displayed smaller behavioral re-
sponses to the physical exam than to the heel prick.
Finally, some characteristics of the immunization and
heel-prickparadigms shouldbenoted. 1)Vaccinationmay
lead to hpa activation by either the painful pinprick or the
immunechallenge. Immunechallenge, suchas tetanusvac-
cination, usually results in maximum cortisol increases
about 4 to 5 h after injection (195). However, in both
studies that used the immunization paradigm, saliva sam-
pleswere collected as soon as 20min after vaccination and
exhibited increased cortisol levels (179, 180). Therefore,
the painful pinprick seems to have elicited the hpa axis
response. 2) The immunization and the heel-prick para-
digms are not fully comparable. On the one hand, the
squeezing of the heel instead of the sharp lancing itself is
the most stressful event during the heel-prick procedure
(196). Consequently, one might hypothesize that the vac-
cination is not as stressful as the heel-prick procedure be-
cause squeezing is not required. On the other hand, rou-
tine immunization injections have been described as the
most common painful medical procedure in childhood
(197). However, the stress-induced rises from baseline in
cortisol, amounting to approximately 60 to 100%, are
roughly comparable in the untreated newborns in the vac-
cination and heel-prick paradigms (171, 179, 188). The
inconsistent results of the studies that used vaccination as
a pain-related stressor (179, 180) may therefore not be
rooted in the paradigm chosen, but in the different study
characteristics as described in SectionV.B. In sum, the two
main pain-related stress paradigms used, that is heel prick
and vaccination, elicit comparable endocrine responses.
4. Pain vs. pharmacological challenge
When comparing results from studies using pharma-
cological challenge vs. painful stimulation, it is striking
that in infants exposed to synthetic glucocorticoids in
utero compared with controls, pharmacological stimula-
tion revealed at best only mildly suppressed cortisol reac-
tivity 1 wk postpartum, whereas painful stimulation re-
vealed sustained inhibition of cortisol reactivity up to 4
months of age. One reason for this findingmay be that the
applied pharmacological tests are not able to reveal pro-
cesses that takeplace above thehypothalamic level. There-
fore, hpa axis changes detected under painful, but not
under pharmacological, stimulation may reflect reduced
input to the hypothalamus from higher levels (e.g., limbic
system, cortical structures).
C. Influence of glucocorticoid dose on hpa function
Comparing the studies presented in the previous sec-
tions, there is quite large variation in numbers of antenatal
treatment courses and total doses of glucocorticoids used
(see SupplementalMaterials 3, 4, and5). Someof the stud-
ies assessed whether number of antenatal glucocorticoid
treatment courses or total dose of the administered sub-
stance influenced basal hpa function or hpa axis reactivity
in the fetus or newborn.
There is evidence for an inverse association between
number of antenatal glucocorticoid treatment courses or
total dose of the substance administered and hpa activity
at baseline or after pharmacological and painful stimula-
tion in the fetus and newborn. That is, exposure to a rel-
atively large amount of synthetic glucocorticoids in utero
is associatedwith relatively lowbasal or reactive hpa func-
tion (68, 147, 157, 172, 187, 198).However, somegroups
did not observe a negative association between number of
antenatal glucocorticoid treatment courses or total dose
of the substance administered and specific secretagogues
of fetal and newborn hpa function at particular time
points at baseline or after stimulation by hCRH, ACTH,
and metyrapone within the first weeks postpartum (166,
167, 169, 170, 174, 180, 186, 199). In a recent study, Ng
et al. (167) even report that cortisol concentrations, as
measured after 1 wk postpartum at baseline and after
hCRH stimulation, are only lower in infants exposed to
one or two (but not in infants exposed to more than two)
glucocorticoid doses compared with unexposed individ-
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uals, leading to the conclusion that low glucocorticoid
doses may have a different impact on hpa function com-
pared with high glucocorticoid doses.
Taken together, approximately50%ofall studies look-
ing at the effects of the amount of substance administered
on basal or reactive hpa function find that high levels of
synthetic glucocorticoids aremore likely than low levels to
have a suppressive effect on basal hpa activity and endo-
crine stress reactivity in the fetus and newborn. There is
evidence that it is the total amount of synthetic glucocor-
ticoids administered rather than the number of antenatal
glucocorticoid courses that underlies this association
(143). The influence the amount of synthetic glucocorti-
coids exerts on fetal and infant hpa axis may partially
explain discrepant results of the reviewed studies pre-
sented in the previous sections.
Restrictingthesynthesis tostudieswitheitherrandomized
study assignment or comparability between exposed and
controls revealed thatone (187)of the three identifiedstudies
shows that high levels of synthetic glucocorticoids are more
likely than lowlevels tohaveasuppressiveeffectonbasalhpa
activity and endocrine stress reactivity, in the fetus and new-
born, while the other two studies (169, 170) do not.
Restricting the synthesis to studieswithhomogeneity of
type of treatment and treatment indication revealed that
five (68, 147, 172, 187, 198) of the 11 identified studies
show that high levels of synthetic glucocorticoids aremore
likely than low levels to have a suppressive effect on basal
hpa activity and endocrine stress reactivity in the fetus and
newborn, whereas the other six studies (166, 167, 169,
170, 174, 199) do not report such an association.
Restricting the synthesis to studies with large sample size
revealedthat five (68,147,157,187,198)of the10identified
studies show that high levels of synthetic glucocorticoids are
more likely than low levels to have a suppressive effect on
basal hpa activity and endocrine stress reactivity in the fetus
and newborn,whereas the other five studies (166, 167, 169,
170, 199) do not report such an association.
In sum, sensitivity analysis revealed that studies with
higher quality are less likely to show that high levels of
synthetic glucocorticoids comparedwith low levels have a
stronger suppressive effect on basal hpa activity and en-
docrine stress reactivity in the fetus and newborn.
D. Influence of time between glucocorticoid treatment
and assessment of hpa function
The time interval that has elapsed between intrauterine
exposure to synthetic glucocorticoids andbirthorhpaaxis
assessmentmay influence the observed effects of synthetic
glucocorticoids on hpa axis. Some authors have gone fur-
ther into this issue. It is of note that they have defined the
time intervals inconsistently, starting either with the first
or last dose of glucocorticoid treatment. Therefore, com-
parisons between studies should be drawn with caution.
In cord blood, ACTH, DHEA-S, and cortisol concen-
trations are suppressed in infants deliveredwithin 24 h of,
and up to 1 wk after, antenatal glucocorticoid adminis-
tration, mostly compared with longer time intervals (59,
68, 125, 143, 145, 150, 152, 154, 155, 160, 166). The
concentration of CRH in cord blood is significantly lower
in those samples collected within 24 h of betamethasone
administration comparedwith controls. In contrast, CRH
concentrations are significantly higher relative to controls
in cord blood obtained more than 24 h and 1 wk after the
last treatment dose (150). This increase of CRH concen-
trations might be rooted in a decreased negative feedback
regulation of the hpa axis due to low circulating cortisol
concentrations.
In amniotic fluid obtainedduringpregnancyor at birth,
the effects of the time between treatment and birth or sam-
ple collection on the concentration of cortisol are similar
to those observed in cord blood (59, 145, 150, 154). In-
terestingly, in contrast to findings in cord blood, ACTH
concentrations in amniotic fluid are not significantly dif-
ferent from control values through 48 h after the last dose
of treatment, but there is a significant decrease in ACTH
levels in samples collected within and after 1 wk from last
betamethasone injection (150). The different patterns of
ACTH production in cord blood and amniotic fluid sug-
gest that the ACTH in amniotic fluid may be produced at
a different site than ACTH in cord blood. Finally, there is
no significant effect of betamethasone on CRH levels in
amniotic fluid up to 1wk after treatment (150). This find-
ing is in contrast to the sequence of CRH decrease and
increase within 1 wk after last treatment dose in cord
blood. However, CRH concentrations in amniotic fluid
collected more than 1 wk after betamethasone treatment
are significantly higher than control values (150). This
suggests that a certain time is needed before CRH changes
in blood are seen in amniotic fluid. Again, the different
patterns of CRH levels in cord blood and amniotic fluid
raise the question of whether CRH in amniotic fluid may
be from a different source than CRH in cord blood.
In the neonate, some studies assessed whether the ef-
fects of intrauterine exposure to synthetic glucocorticoids
on basal hpa function dependon the time interval between
treatment and birth/sample collection. Results from these
studies are equivocal. More than one third of these inves-
tigations report that the longer the time interval between
treatment and birth/sample collection, the greater the sup-
pression of 17-OHP, cortisol, or ACTH relative to con-
trols (125,172,198).Theseobservations contrastwith the
aforementioned results from cord blood and amniotic
fluid. This leads to the question of whether the relation-
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ship, time interval between treatment and sample collec-
tion vs. the suppressive effect on hpa function,may follow
a U-shape: a relatively long time interval is linked to rel-
atively low suppression of hpa activity in utero, but rela-
tively strong suppression of hpa activity in the first post-
natal week. This hypothesis implies that the effects of the
time interval between treatment and birth/sample collec-
tion on pre- and postnatal hpa axis may be mediated by
different mechanisms. However, it also needs to be re-
membered that there are studies in the neonate that
report that the time interval between treatment and
birth/sample collection is either positively associated
with (199) or without influence (160, 170, 171, 181) on
basal hpa activity.
The time interval between antenatal glucocorticoid ad-
ministration and delivery/sample collection does not im-
pact on the extent of the effect of synthetic glucocorticoids
on hpa reactivity to ACTH or metyrapone (170, 175,
186). Similarly, three investigations that evaluated the ef-
fect of the time interval between treatment and delivery or
sample collection on hpa axis, without specifyingwhether
they looked at basal or reactive measures, report nonsig-
nificant results (171, 172, 187).
Interestingly, the influence of the time that has elapsed
between treatment and sample collection has been shown
to depend on the dose administered (167, 187, 200). At
age 2 h in infants delivered 1–72 h after treatment, plasma
cortisol concentrations are lower after three or more
courses than after one or two courses of antenatal glu-
cocorticoids. Cortisol suppression persists for neonates
delivered 73–240 h after the last of multiple doses (200).
Finally, the time interval between the last dexamethasone
dose and delivery is positively associated with serum cor-
tisol concentrations 15 and 60min after CRH stimulation
at 1 wk, but not 2 wk, after birth in infants who received
more than two doses of antenatal glucocorticoids (167).
In sum, relatively short time intervals between treat-
ment and birth/sample collection primarily lead to rela-
tively high suppression of fetal basal hpa function but rel-
atively low suppression of neonatal basal hpa function.
The time lag between glucocorticoid administration and
delivery/sample collection does not seem to have an influ-
ence on hpa axis reactivity within the first weeks of life.
Discrepant findings between the studies reviewed may
partially originate in the different time intervals between
treatment and sample collection that have been used.
Restricting the synthesis to studies with either random-
ized study assignment or comparability between exposed
and controls revealed that two (143, 155) of the four iden-
tified studies that addressed the effect of the time interval
provide evidence for an effect of the time interval between
treatment and birth or sample collection on hpa function,
whereas two studies do not (170, 187).
Restricting the synthesis to studieswithhomogeneity of
type of treatment and treatment indication revealed that
12 (68, 143, 145, 150, 152, 154, 155, 166, 167, 172, 198,
199) of the 15 identified studies that addressed the effect
of the time interval provide evidence for an effect of the
time interval between treatment and birth or sample col-
lectiononhpa function,whereas three studies donot (170,
171, 187).
Restricting the synthesis to studies with large sample
size revealed that eight (68, 125, 143, 152, 166, 167, 198,
199) of the 11 identified studies that addressed the effect
of time interval provide evidence for an effect of the time
intervals between treatment and birth or sample collec-
tion on hpa function, whereas three studies do not (170,
181, 187).
In sum, sensitivity analysis provides evidence that the
time interval between treatment and birth or sample col-
lection influences hpa function, which is in line with the
picture provided by the synthesis including all available
studies.
E. Summary of the sensitivity analyses
The sensitivity analyses revealed that the integrated
findings fromhigher quality studies aremostly in linewith
thepicturepresentedby the total numberof available stud-
ies.Most notably, the higher quality studies even provided
slightly stronger evidence for effects of intrauterine expo-
sure to glucocorticoids on hpa axis in the offspring. The
only exception was the dose effect, which was less pro-
nounced in the higher quality studies compared with the
total number of studies.
V. Discussion
A. Main results of the studies
This review of human studies has revealed that intra-
uterine exposure to synthetic glucocorticoids reduces fetal
and, in some cases, newborn and infant hpa activity under
basal conditions, and, more consistently, after pain-re-
lated stress. These effects may be more marked with a
higher total amount of glucocorticoids administered and
vary with the time between glucocorticoid exposure and
hpa axis assessment. Although reduced basal hpa function
seems to recover within the first 2 wk postpartum, there is
preliminary evidence that blunted hpa axis reactivity to
pain-related stress persists throughout the first 4 months
of life.
Apart of the identified studies showedweaknesseswith
respect to different aspects of study quality. However, our
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conclusionsarebasedona largenumberof studies, and the
sensitivity analyses revealed that the findings from higher
quality studies are in line with the picture presented by
the total number of available studies. In light of the
clinical relevance of prenatal glucocorticoid treatment
and hpa activity, future high-quality research is ur-
gently warranted.
B. Overall study limitations and alternative explanations
for observed results
Some overall methodological issues complicate the in-
terpretation of the reviewed studies, as discussed in the
following sections.
1. Study design, including confounding
Due to ethical constraints, in most studies pregnant
women could not be assigned randomly to the glucocor-
ticoid treatment or no-treatment groups. In fact, the ma-
jority of studies employed quasi-experimental study de-
signs, allocating women on the basis of the clinically
prescribed treatment—that is only those women whose
attending obstetrician decided to start glucocorticoid
treatment due to clinical indication were considered as
candidates for the glucocorticoid treatment group,
whereas those without treatment indication and, hence,
no glucocorticoid treatment were considered as candi-
dates for the control group (“confounding by indica-
tion”). Thus, it cannot be excluded that the endocrine
effects observed in the fetus or newborn are a consequence
of the clinical indication (or other factors linked to it)
rather than the antenatal glucocorticoid.
One of the main reasons for glucocorticoid treatment
during pregnancy is prophylactic preparation for preterm
birth; accordingly, in most of the reviewed studies, glu-
cocorticoid treatment has been indicated by risk of pre-
term delivery. One of the factors linked to this treatment
indication is the length of gestation, which in the majority
of cases is shorter in glucocorticoid-treated fetuses than
in untreated fetuses. Consequently, in some studies re-
viewed, treatment groups were not comparable regarding
gestational age. Such group differences are problematic
because fetal and newborn hpa activity is subject to dy-
namic changes and the adrenal cortex dramatically re-
models around birth (see Section II.D). Thus, it cannot be
excluded that results have partly been influenced by dif-
ferent gestational ages in treated and untreated fetuses.
Onemethod to deal with this problemhas been applied by
Davis et al. (188): their glucocorticoid group covered sub-
jects born between 28 and 30 wk gestation, whereas due
to scarcity of infants of equal gestational age without pre-
natal glucocorticoid treatment their control group con-
sisted of infants born between 33 and 34wk gestation. To
account for this limitation, group comparisons were only
performed between glucocorticoid-treated infants as they
reached postconceptional ages of 33 to 34wk and control
infants at birth. However, different postnatal ages still
complicate the interpretation of the findings.
Gestational age has indeed been shown to influence the
effects that intrauterine exposure to synthetic glucocorti-
coids exerts onhpa function (166, 187).Umbilical cortisol
concentrations have been reported to be reduced only in
treated preterm, but not in treated term, infants compared
with term controls (148), raising the question of whether
endocrine suppression observed after prenatal glucocor-
ticoid exposure is primarily due to immaturity rather than
to the treatment per se. However, recently, another group
observed the opposite effect: that is, fetal hpa suppression
after intrauterine glucocorticoid exposure was more pro-
nounced in fetuses born at 32 to 36 wk gestation than in
fetuses born at 26 to 32 wk gestation, indicating that glu-
cocorticoid exposure also takes effect in more mature fe-
tuses (149).Moreover, infantswhowerebornbetweenwk
30 and 33 had a median 17-OHP value that was lower in
the prenatally treated group within the first postnatal
week; conversely, in infants born before wk 30, the me-
dian 17-OHP value was higher in the treated group (181).
These observations indicate that it is not prematurity, but
rather the glucocorticoid treatment that leads to the re-
duction of hpa activity. In support of this interpretation,
other investigations have demonstrated hpa-suppressing
properties of intrauterine synthetic glucocorticoids when
comparing infants with largely comparable gestational
ages (65, 152, 169, 175, 185).
Some investigations were indeed based on experimen-
tal study designs (151, 155, 170, 187). Moreover, the
methodological limitations in the studies that used quasi-
experimental study designs have in part been overcome by
applying various approaches: some investigations 1) in-
cluded only uncomplicated pregnancies (59); 2) assigned
fetuses endangered of preterm delivery to all study groups
(e.g., Refs. 145, 150, and 176); 3) used control groups
consisting of women with glucocorticoid treatment indi-
cation but no treatment (69, 156–158); or 4) looked at the
effectsof theamountof substanceadministeredor the time
interval between treatment and birth or sample collection
on hpa function (see Sections IV.C and IV.D). Overall,
findings from these studies support the interpretation that
endocrine effects observed in the fetuses and infants are
due to the glucocorticoid treatment itself.
Due to practical constraints, some studies were not
even able to fully tap the potential of the quasi-experi-
mental study design. In these cases, concise conclusions
are further hindered by the absence of appropriate control
groups: onlya fewauthorsused external controls,whereas
others included infants treated remotely, or even fully
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passed on a control group, as for instance in case reports.
Finally, for practical reasons, most of the studies did not
use placebo-controlled study designs. In such cases, it can-
not be excluded that the treatment procedure, rather than
the substance itself, led to changes in fetal or newborn hpa
function, although this concern seems to be rather implau-
sible, especially when considering the lasting effects.
To overcome limitations of the (quasi-experimental)
study design, future studies should apply placebo-con-
trolled experimental study designs, if possible. Research-
ersmay, due to the ethical constraints that have beenmen-
tioned above, vary number of treatment courses rather
than glucocorticoid treatment itself, as long as no clear
evidence exists that favors a defined number of courses.
There are already large clinical trials [e.g.,Maternal Infant
and Reproductive Health Research Unit, Multiple
Courses of Antenatal Corticosteroids for Preterm Birth
Study (MACS) (201)] ongoing that implement such an
experimental study design. If experimental trials are not
feasible, then, as an alternative, appropriate control
groups consisting of subjects with gestational glucocorti-
coid treatment indication but no treatment should be in-
cluded, if available. Finally, effects of varying doses and
time intervals between treatment and hpa assessment
should be assessed.
2. Sample size
The sample size varied considerably between studies.
Some of the authors reported relatively small sample sizes
(see Supplemental Materials 3, 4, and 5). Findings from
these investigations should be interpreted with caution
because their statistical uncertaintymaybe ratherhighdue
to the small sample size.
3. Long-term follow-up
Infant hpa function has predominantly been assessed
immediately after birth and up to the first 2 months post-
partum. However, little is known about the long-term
consequences of intrauterine exposure to synthetic glu-
cocorticoids on endocrine function in humans. Any long-
term effects might well play a role in the long-term health
consequences that have been observed in treated individ-
uals and in the onset of other stress-related diseases, as
discussed in the next section.
More follow-up studies in treated individuals are
strongly needed to evaluate hpa function after antenatal
exposure to synthetic glucocorticoids at various stages of
development.
4. Sex differences
Only one group (69) categorically studied the effects of
antenatal glucocorticoid therapy on cortisol concentra-
tions in cord blood in males and females, whereas most of
the other authors did not even specify the sex of the study
probands. Murphy et al. (69) found comparable endo-
crine patterns in male and female newborns. However,
males and females may be differentially affected by ante-
natal glucocorticoid treatment, given the recent observa-
tion in pigs that elevated maternal cortisol levels during
mid and late gestation impact on the offspring’s hpa axis
in a sex-specific manner (202). Moreover, placental 11-
HSD2 activity after antenatal glucocorticoid treatment is
influenced in a sex-specific manner in humans (69), as
described in the next section. Finally, emerging evidence
indicates that programming effects of an adverse intra-
uterine environment ingeneral arehighly sex-specific (21).
Therefore, there is a strong need for investigations com-
paring the effects of antenatal glucocorticoid treatment in
males and females.
5. Glucocorticoid preparation
The antenatal glucocorticoids are administered in dif-
ferent preparations (e.g., a dual formulation containing
betamethasone acetate and phosphate or pure betametha-
sonephosphate) that differ in their pharmacokinetic prop-
erties (see Section II.B.1) andmay thus differentially affect
fetal and infant hpa (re-)activity.However,wedidnot find
evidence for hpa axis differences depending on the prep-
aration used, although incomplete documentation of
preparation in a number of articles hindered comparisons.
6. Heterogeneity of studies
Finally, investigations differedwith regard to other im-
portant study characteristics and aspects of study quality,
suchas treatment indications, glucocorticoidagents, prep-
arations, intrastudy heterogeneity of these factors, route
of drug administration, analytes of hpa axis chosen, time
of hpa axis assessment, and the compartment inwhich the
analyte was measured (see Supplemental Materials 3, 4,
and 5). Moreover, we cannot exclude further potential
sources of heterogeneity on which information is lacking
[e.g., whether basal hpa function in newborns was as-
sessed under fasting conditions, the stage of perinatal re-
modeling of the adrenocortex, diurnal variability of hpa
activity (203)]. These differences have limiting as well as
supporting properties. On the one hand, they hamper
comparisons between studies because the effects of these
differences may override the rather subtle effects of the
glucocorticoid treatment itself. On the other hand, all of
these factors serve to improve the studies’ ecological va-
lidity, broaden the insight into the complexity of factors
that modify the impact of antenatal glucocorticoid treat-
ment on hpa function in the fetus and newborn, and offer
amore specific analysis of contributingparameters.Taken
together, large, randomized, placebo-controlled trials
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with concealment of study allocation on short- and long-
term consequences of antenatal exposure to synthetic glu-
cocorticoids on male vs. female hpa activity are strongly
needed in humans. If feasible, the ecological validity
should be broadened by including a wide range of treat-
ment regimes and outcome measures in homogenous
subgroups.
7. Bias and generalizability
Because we applied broad inclusion criteria, we mini-
mized the risk of bias due to selective exclusion of studies.
Still, publication bias represents a threat to the validity of
our findings, especially becausewe includedobservational
studies into our systematic review. Indeed, findings from
observational studies are at a higher risk of publication
bias than randomized trials (204). However, we reduced
some of the potential of publication bias by taking study
design into account as quality criterion. Similarly, we ac-
counted for effects of sample size. Sample size has been
shown to be negatively associated with publication bias
(205, 206).
With regard to generalizability, in the majority of stud-
ies, glucocorticoidswere administered topregnantwomen
with certain medical conditions (i.e., risk for preterm de-
livery, risk for CAH, CDH, asthma). Therefore, general-
izability of the results to offspring of womenwho received
glucocorticoids due to other reasons may be limited.
C. Mechanisms of hpa axis suppression
A number of studies have assessed the physiological
effects of intrauterine exposure to synthetic glucocorti-
coids at diverse levels of the fetal hpa axis-placental unit
and related these to the putative mechanisms via which
this can lead to the reduction of the fetal and newborn hpa
activity. Some groups looked at the impact of intrauterine
exposure to synthetic glucocorticoids on the activity of
placental 11-HSD2, the major enzyme that limits the
amount of glucocorticoids that pass frommother to fetus.
Others have asked whether changes in hpa axis activity
were short-term effects of synthetic glucocorticoids while
they were present in blood or lasting effects after they had
been cleared. A third approach has been to focus on the
alterations of fetal and newborn hpa axis structures and
secretagogues that have been shown to occur after ante-
natal glucocorticoid treatment.
1. Placental 11-HSD2
The enzyme 11-HSD2 inactivates maternal glucocor-
ticoids at the placental level, thereby reducing the amount
of cortisol that passes from mother to fetus. Because syn-
thetic glucocorticoids have been shown to increase pla-
cental 11-HSD2 activity, maternal glucocorticoids may
be even more strongly prevented from transplacental pas-
sage in glucocorticoid-treated pregnancies (see Section
II.B.3). The observed lower cortisol concentrations in
cord blood after prenatal glucocorticoid treatment (see
Section IV.A.1) may thus be due to reduced cortisol con-
centrations of maternal origin. However, due to under-
supply with maternal glucocorticoids, the fetal hpa axis
might be anticipated to up-regulate rather than down-
regulate its activity in the medium term. Therefore, re-
duced transplacental passage of maternal glucocorticoids
due to an amplified placental barrier after administration
of synthetic glucocorticoids does not seem to be an obvi-
ous candidate mechanism underlying the medium-term
hypocortisolism.
2. Short-term vs. long-term effects of synthetic
glucocorticoids on hpa axis
Once having passed the placental barrier, synthetic glu-
cocorticoids would be anticipated to have two opposing
effects in the fetus.
First, due to their own glucocorticoid properties, they
might generate a transient hypercortisolemic state in the
fetus until they have been cleared.
To determine how long synthetic glucocorticoids are
biologically active, one investigation looked at the circu-
lating glucocorticoid bioactivity (GBA), made up of syn-
thetic and endogenous glucocorticoids, in cord blood. The
authors demonstrate that infants born within 12 h after
the last betamethasone dose display an average 4-fold
higher GBA than infants with more than 7 d since the last
dosebeforebirthorwithout treatment (147). In the former
infants, 85% of the total GBA is attributable to synthetic
glucocorticoids. When 24 to 48 h elapse between the last
glucocorticoid dose and birth, in cord blood GBA is pri-
marily attributable to endogenous cortisol, indicating that
exogenous glucocorticoids no longer exert acute effects on
the fetus.
Secondly, in contrast to generating a hypercortisolemic
state in the fetus, synthetic glucocorticoids might, by in-
hibiting the fetal hpa axis, induce a hypocortisolemic state
in the fetus.
The question arises as to whether these oppositional
effects of synthetic glucocorticoids, putatively inducing
either a hyper- or hypocortisolemic state, have compara-
ble potency and occur simultaneously, thereby balancing
each other out and resulting in a net neutral effect on
endocrine state, or whether one of them outweighs the
other.
To directly compare synthetic and endogenous glu-
cocorticoid levels, Ballard et al. (143) looked at the GBA
in relation to the detectable concentrations of betametha-
sone in cord blood and simultaneously measured both
betamethasone concentrations and GBA at different time
lags from treatment.Mean betamethasone levels aremax-
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imal during the first 48h, afterwhich they start to decrease
and show an inverse relationship with the levels of endog-
enous cortisol. Betamethasone is not detected in any sam-
ple obtained beyond 60 h of the last dose. Consequently,
unbound GBA is maximal 1 h after treatment and falls
below untreated levels by 60 h after treatment, when be-
tamethasonehasbeen cleared.These findings indicate that
recovery from hpa hypofunction takes longer than clear-
ance of betamethasone, thus persisting beyond exposure
to synthetic glucocorticoids.
There are twomain conclusions to be drawn from these
observations. First, the reduction of fetal and newborn
hpa activity may be a direct consequence of the inhibiting
effects of the synthetic glucocorticoids administered to the
mother while they are present in blood. Evidence for this
hypothesis comes from a number of investigations that
studied the effects of synthetic glucocorticoids soon after
their administration, before they could have been cleared
from blood (143, 147, 150, 152, 154, 155). However, a
considerable number of studiesmeasured hpa reactivity at
least 72 h after birth at the earliest, when synthetic glu-
cocorticoids would be expected to have been cleared from
blood according to the findingsmentioned above from the
groups of Kajantie et al. (147) and Ballard et al. (143).
Indeed, these studies reported lasting adrenal suppression
beyond the clearance of the synthetic glucocorticoids
(152, 167, 171, 172, 180, 187, 188, 199), leading to the
second of the main conclusions, i.e., that hpa activity be-
comes independent from exogenous influence, whereas
changes in structure and function of hpa axis or brain
regions involved in the regulation of hpa axis develop that
keep the axis’ activity low.
3. Alterations in hpa axis
Different alterations in hpa axis structures may under-
lie the reduced hpa activity observed in fetuses and infants
prenatally treated with glucocorticoids. According to
findings in patients with diverse stress-related disorders,
potential changes may be 1) reduced biosynthesis or re-
lease of hpa axis secretagogues or placental CRH as one
main stimulator of the fetal endocrine stress system, re-
sulting in decreased activation of their particular target
receptors; 2) hypersecretion of CRH or ACTH with an
overcompensatory down-regulation of their respective
target receptors and a subsequently decreased stimulation
at the adrenal level; 3) an increased negative feedback sen-
sitivity to glucocorticoids at pituitary and hypothalamic
level or a decreased positive feedback sensitivity at pla-
cental site; 4) a decreased availability of free cortisol; or 5)
morphological changes at either level of the hpa axis or the
placenta (207, 208).
There is preliminary evidence for some of these mech-
anisms underlying hypocortisolemic patterns in human
newborns exposed to synthetic glucocorticoids in utero. 1)
In support of a primary adrenal insufficiency, two authors
found decreased basal cortisol concentrations, along with
normal levels of ACTH, in infants prenatally exposed to
synthetic glucocorticoidswithin the firstweekpostpartum
(167, 168). Findings of decreases in both cortisol and
ACTHconcentrations, however, rather point to a second-
ary adrenal insufficiency (150, 156). 2) Other studies sug-
gest an adaptive CRH- or ACTH-receptor down-regula-
tion when reporting decreased cortisol responses in the
CRH stimulation test (172). 3) Moreover, an increased
unbound glucocorticoid bioactivity after betamethasone
treatment (147) may probably lead to increased GR bind-
ing the at pituitary or hypothalamic level, resulting in a
subsequently increased negative feedback that could ex-
plain the reduced hpa activity. However, the reported 10-
to 20-fold rise in plasma 11-deoxycortisol after metyrap-
oneadministration in infants exposed tobetamethasone in
utero hints to unchanged feedback sensitivity at the pitu-
itary and hypothalamic level (146). To our knowledge, as
yet no study has looked at whether infants displaying a
hypocortisolemic phenotype have a compensatory in-
creased sensitivity to glucocorticoids in target tissues other
than the hpa axis itself. This issue would be interesting
because glucocorticoid sensitivity has been shown to vary
tissue specifically (209), and the clinical risk of the ob-
served reduced hpa activity would appear to be closely
linked to the capability of the remaining amount of en-
dogenous glucocorticoids to take effect in their target tis-
sues. If glucocorticoid sensitivity of other tissues and cell
types increases in a compensatory manner, no adverse
consequences will be anticipated. 4) Finally, one study
found significantly decreased CBG capacity in cord blood
in those samples obtained within 24 h of glucocorticoid
treatment and, irrespective of the time between glucocor-
ticoid treatment and assessment, unchanged CBG capac-
ity in cord blood, as well as reduced CBG capacity in am-
niotic fluid (210). These findings suggest an increased
rather than adecreased availability of free plasma cortisol,
which obviously cannot explain the phenomenon of re-
duced hpa activity in infants treated with synthetic glu-
cocorticoids in utero.
In sum, there is evidence that different alterations of
hpa axis, including primary or secondary adrenal insuffi-
ciency or (compensatory) down-regulation of receptors at
higher hpa axis levels, may underlie the observed hypo-
cortisolemic phenotype in infants exposed to synthetic
glucocorticoids in utero. There is, however, only incon-
clusive evidence for an increased negative feedback sensi-
tivity of the hpa axis to glucocorticoids or no hint for
changes in CBG capacity.
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4. Alterations at higher brain sites
At least in animals, moderate amounts of betametha-
sone, dexamethasone, and prednisolone penetrate the
brain poorly because of P-gp activity at the level of the
blood-brain barrier (79–83). Synthetic glucocorticoids
may, therefore, exert their effects on hpa axis predomi-
nantly at thepituitary level,where they are retained inhigh
amounts, because they are not bound to CBG (82, 211).
Nonetheless, it is likely that small amounts of synthetic
glucocorticoids are able to pass the blood-brain barrier.
Furthermore, the fetal blood-brain barrier is still more
permeable for synthetic glucocorticoids than is the post-
natal blood-brain barrier (see Section II.B.3). In sum,
small amounts of synthetic glucocorticoids may well pass
the fetal blood-brain barrier and act on central GR. This
bypass, which becomes relevant if a sufficient amount of
synthetic glucocorticoid is administered, might underlie
the observed changes in cognitive, psychological, andmo-
tor function after exposure to synthetic glucocorticoids in
utero (see Section V.F and Refs. 5 and 7).
In animal studies, functional changes in the hpa axis
after intrauterine exposure to synthetic glucocorticoids
have been demonstrated to be associated with changes at
higher brain levels, including alterations in diverse brain
structures involved in hpa axis regulation, particularly the
hippocampus, changes in glucocorticoid receptor expres-
sion, and variations in other neuroendocrine and neuro-
transmitter systems (4, 5, 21), rather thanbeing associated
with primary biological variations of hpa axis structures.
For example, it has been shown in the guinea pig that
hippocampal GR and MR mRNA expressions are influ-
enced sex-specifically by intrauterine exposure to syn-
thetic glucocorticoids (212, 213). However, in humans,
GR and MR expression levels are comparable in prena-
tally treated or untreated newborns that died within 4 d
after delivery (95). Because the sample size in the latter
study was rather small, more studies are needed to learn
about the effects of synthetic glucocorticoids on fetal GR
and MR expression in humans.
Taken together, despite increasing placental 11-
HSD2 activity after exposure to synthetic glucocorticoids
in utero, the latter easily pass the placental barrier. While
inducing a short-term hypercortisolemic state in the fetus
due to their glucocorticoid properties, synthetic glucocor-
ticoids concomitantly reduce hpa function. Furthermore,
synthetic glucocorticoids are capable of altering the en-
docrine stress system, such that it operates independently
from the acute influence of synthetic glucocorticoids in the
intermediate term. The hpa reduction might be due to
various biological mechanisms. Moreover, it cannot be
finally excluded that changes in hpa function after intra-
uterine exposure to glucocorticoids are secondary to their
therapeutic effects. For example, one may speculate that
administration of glucocorticoids to pregnant women re-
duced respiratory stress and hypoxia in the offspring,
thereby decreasing fetal hpa function. Interestingly, there
was no association between intrauterine exposure to glu-
cocorticoids and hpa reactivity to respiratory stress (see
Section IV.B.2), the reduction of which is, however, the
major clinically desired effect of maternal glucocorticoid
treatment during pregnancy on the offspring. More stud-
ies are needed to look further at the mechanisms that un-
derlie reduced hpa function after intrauterine exposure to
synthetic glucocorticoids in humans. These future studies
should assess biosynthesis, secretion, and biological ac-
tivity of diverse hpa axis secretagogues and the number
and function of their respective receptors, including, if
feasible, postmortem analyses of receptor programming
and brain morphology.
D. Integrative model of altered hpa function due to
intrauterine exposure to synthetic glucocorticoids
The findings from studies across different assessment
paradigms that have been presented in Section IV provide
the basis for the followingmodel. Intrauterine exposure to
synthetic glucocorticoids leads 1) to reduced fetal hpa axis
activity at different hpa axis levels, as measured in cord
blood and amniotic fluid; 2) to a subsequent recovery of
basal hpa axis activity at the level of the pituitary, as in-
dicated by normalized ACTH concentrations within the
first week postpartum, but with continuing reduced ad-
renocortical activity; 3) to a subsequent recovery of basal
hpa axis activity at the level of the adrenocortex, as indi-
cated by normalized (or even increased) basal concentra-
tions of indicators of cortisol synthesis or secretion by the
end of the second week postpartum; and 4) to ongoing
reduced hpa axis reactivity during the first months of life
that probably originates from changes at suprapituitary
levels, as is suggested by studies applying pharmacological
and psychological challenge.
E. Clinical implications: adverse health consequences of
reduced hpa activity during infancy
Suppressed fetal and infant hpa function may, due to
alterations in tissue exposure to endogenous glucocor-
ticoids, result in an altered rate of development and/or
in acute or delayed health impairment. This question
has, to our knowledge, not been comprehensively ad-
dressed to date. Nonetheless, the functional physiology
of endogenous glucocorticoids and several experimen-
tal and clinical observations indicate that compromised
endocrine activity at an early stage of life will be of
clinical relevance.
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1. Physiological evidence
Overall, endogenous glucocorticoids regulate the func-
tion of almost all organ systems. For instance, they reg-
ulate lipid, protein, and carbohydrate metabolism, and
impact on cardiovascular, neurobiological, and immuno-
logical function. Most importantly, they maintain bodily
homeostasis in stressful situations (23). Against this phys-
iological background, it appears that reduced hpa func-
tion in infants exposed to synthetic glucocorticoids in
utero may indeed compromise a wide variety of bodily
functions.
2. Experimental evidence
There is experimental evidence that 3-month-old in-
fants who show a cortisol decrease during a learning task
have significantly impaired memory relative to infants
who show a cortisol increase, indicating that appropriate
cortisol reactivity is required during learning to guarantee
adequate advancement (214). It can be hypothesized that
reduced hpa axis reactivity in infants treated with syn-
thetic glucocorticoids in utero is not restricted to painful
stressors (see Section IV.B.3) but also occurs during cog-
nitive tasks, thereby impairing learning and memory. To
our knowledge, this issue has not been studied to date.
3. Clinical evidence
The clinical pictures of adrenal insufficiency or hypo-
function may allow for assessment of the medical rele-
vance of early life hpa hypofunction due to intrauterine
exposure to synthetic glucocorticoids. Glucocorticoid de-
ficiency due to apparent adrenal hypofunction occurs in
diverse clinical conditions, such as primary and secondary
adrenal insufficiency (215, 216) and CAH (217), at di-
verse life stages.These conditions comprise a largenumber
of symptoms, including fatigue, gastric pain, nausea, and
myalgia, indicating that adrenal insufficiency is indeed ca-
pable of compromising health. Adrenal insufficiency is
usually characterized by 1) long duration of illness and 2)
pronounced intensity of glucocorticoid suppression. By
contrast, 1) the reduction of baseline hpa function after
exposure to synthetic glucocorticoids in utero is probably
transient, and 2) the magnitude of inhibition of hpa func-
tion is rather subclinical. Taken together, clinical models
of adrenal insufficiency may not be informative about the
putative role of early endogenous glucocorticoid defi-
ciency in pathogenesis.
4. Developmental evidence
In a series of studies, atopic diseases have been linked to
attenuated cortisol stress responses in children aged 7 to
14 yr (218, 219) and adults (220). Interestingly, elevated
hpa reactivity has been observed in infants with positive
parental atopic heritage and increased IgE concentrations
in cord blood 3 d postpartum, suggesting that increased
endocrine stress reactivity is linked to atopic disposition in
neonates (192). In their recent study, the authors specu-
lated that with the onset or chronification of the disease,
hpa axis might switch from a hyperactive state to a hypo-
reactive state (192). Fries et al. (207) recently discussed
this developmental model in detail, arguing that a switch
in hpa activity might be due to overadjustment of the en-
docrine system. According to their model, it can be hy-
pothesized that newborns exposed to glucocorticoids in
utero similarly overadjust endocrine activity; in contrast
to the patientswith atopic diseases, individuals exposed to
synthetic glucocorticoids in utero may start with sup-
pressed hpa function and switch to increased activity later
on. First evidence for this hypothesis comes from two
groups that studied hpa function in 4-month-old infants
and30-yr-old adults, demonstrating apositive association
between intrauterine glucocorticoid exposure and basal
(morning) cortisol concentrations (180, 184).
If the hypothesis that hpa axis switches from a hypo- to
a hyperactive state at some point in life holds true, it is of
note that not only decreased, but also excessive and sus-
tained cortisol secretion has long been linked to a wide
range of stress-related diseases, primarily depression, hy-
pertension, osteoporosis, metabolic syndrome, cardio-
vascular disease, gastrointestinal disease, and suppres-
sion of reproductive, growth, and immune function (20,
221–223).
This association between hypercortisolism and pathol-
ogy has recently been observed in children as well, sug-
gesting that the relationship is not just a function of
adult pathology. A subset of small for gestational age
children with high serum cortisol/cortisone ratio have
poor catch-up growth within the first 7 yr of life, high
serum total and low-density lipoprotein cholesterol, a
high homeostasis model assessment insulin resistance in-
dex, and early pubertal stage (224).
In sum, there is first evidence for hpa axis switching
fromahyper- to a hypoactive state due to overadjustment.
Accordingly, one might hypothesize that reduced hpa
function in infants exposed to synthetic glucocorticoids in
utero would conversely switch to a hyperactive state at a
later time. If this hypothesis is true, affected infantsmaybe
vulnerable to stress-related diseases that are associated
with hypercortisolemic phenotypes, including depression
and metabolic and cardiovascular diseases.
5. Evidence from postnatal glucocorticoid exposure
The question of whether a blunted endocrine system
early in life impacts on development can be indirectly an-
swered froma number of investigations studying the long-
term consequences of early postnatal glucocorticoid ther-
apy due to respiratory distress because this treatment has
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repeatedly been linked to suppression of hpa function
(e.g., Refs. 225–230). Taken together, infants neonatally
treated with dexamethasone for respiratory distress ex-
hibit poorer behavioral and cognitive performance and
show compromised neuromotor and psychomotor devel-
opment up to school age (e.g., Refs. 231–234). However,
to date the question remains unanswered as towhether the
observed suppressionofhpa function in infants exposed to
synthetic glucocorticoids after birthmediates the reported
developmental outcomes of the treatment.Moreover, pre-
and postnatal glucocorticoid treatments may not be com-
parable because postnatal therapy has different treatment
indications that might themselves influence hpa axis func-
tion andusually lasts longer thanprenatal therapy.Hence,
stronger effects would be anticipated under postnatal
treatment.
Taken together, there is first experimental and clinical
evidence that reducedhpa function early in lifemay impair
development and health in the short term and in the long
term.However, more studies are needed to assess the clin-
ical implications of altered tissue exposure to endogenous
glucocorticoids in fetuses and newborns due to antenatal
treatment with synthetic glucocorticoids.
F. Hpa axis dysregulation as a mechanism linking
intrauterine environment to compromised health
Exposure to synthetic glucocorticoids in utero has been
linked to impaired fetal growth (235) andmodulated fetal
immune function (149), indicators of compromised cog-
nitive (236, 237), neurological (238), and psychological
function (239) and increased blood pressure (240) into
adolescence (5, 7). Given that 1) exposure to synthetic
glucocorticoids in utero impacts on health and develop-
ment in humans, as has been indicated by these studies; 2)
exposure to synthetic glucocorticoids in utero suppresses
fetal and infant hpa function in humans, as is one major
finding of this review; and 3) reduced hpa function during
infancy is associated with developmental and health im-
pairment in humans (149, 207, 208, 241, 242), the ques-
tion arises as to whether suppressed fetal and infant hpa
function after exposure to synthetic glucocorticoids in
utero may represent a mechanism that links exposure to
synthetic glucocorticoids in the intrauterine environment
to the observed adverse developmental and health conse-
quences. To our knowledge, no animal study and no hu-
man studyhas comprehensively addressed this issue as yet.
Therefore, we cannot conclusively evaluate whether in-
fant hpa axis dysregulation mediates adverse health con-
sequences of antenatal exposure to synthetic glucocor-
ticoids, but there is emerging evidence that this may be
the case.
Alternatively, developmental and health impairments
associated with intrauterine exposure to synthetic glu-
cocorticoids may be mediated by brain regions with GR
expression that are not involved in regulation of the hpa
axis or by other organ systems that express GR. In this
case, changes of the hpa axis may only be an indicator of
these adverse central or peripheral changes but not them-
selves linked to the observed adversities in individuals ex-
posed to synthetic glucocorticoids in utero. Figure 2 illus-
trates the pathways via which intrauterine exposure to
synthetic glucocorticoids may influence development and
health.
G. Relevance of the findings for understanding effects
of psychosocial stress during pregnancy
It is challenging to decide whether intrauterine expo-
sure to synthetic glucocorticoids and intrauterine expo-
sure to stress in various forms, including psychosocial
stress of the mother, effectively result in similar endocri-
nological patterns shortly after birth. Only a few human
investigations measured physiological indices of hpa axis
functioning in offspring after maternal stress during preg-
nancy. In one investigation, prenatal maternal stress has
been shown to be associated with cortisol concentrations
in the offspring at school age (243). Childrenwhosemoth-
ers reported more fear of having a handicapped child ex-
hibit higher cortisol levels than children of mothers who
had reported less fear. This finding would well fit to our
above-described hypothesis that reduced hpa axis activity
early in life will switch to a hyperactive state in later life
due tooveradjustment. In contrast to this hypothesis, new-
borns of mothers with antepartum and postpartum de-
pressive symptoms already show increased cortisol con-
centrations shortly after birth (244).
However, the latter finding needs to be interpretedwith
caution because even healthy individuals having a first-
degree relative with an affective illness and, therefore, be-
FIG 2. A model to illustrate the possible pathways via which
intrauterine exposure to synthetic glucocorticoids can lead to short-
and long-term alterations of hpa function and health impairment. It
should be noted that putative glucocorticoid effects on hpa axis could
be the cause or a concomitant biomarker of the relationship between
treatment and health outcome.
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ing at high risk for a depressive disorder have been shown
to exhibit a hypercortisolemic phenotype (245), suggest-
ing a genetic rather than a stress-induced alteration of hpa
activity in offspring of depressed mothers. More studies
evaluating whether antenatal synthetic glucocorticoids
are a validmodel ofmaternal gestational stress of different
forms are needed in humans.
H. Future studies
As has been discussed in detail in Section V.B, future
human studies on intrauterine programming of hpa func-
tion by synthetic glucocorticoids are needed. Specifically,
there is a strong need for 1) large randomized, placebo-
controlled trials with concealment of allocation on the
effects of exposure to synthetic glucocorticoids in uteroon
the offspring’s hpa function; 2) long-term follow-up of
endocrine function after exposure to synthetic glucocor-
ticoids in utero; 3) investigations addressing sex differ-
ences in susceptibility of hpa axis to intrauterine glucocor-
ticoid exposure; 4) investigations assessing the effects of
intrauterine glucocorticoid exposure on the diurnal vari-
ability of hpa activity, as shown in animal studies (246); 5)
trials that further address the mechanisms of reduced hpa
function after intrauterine exposure to synthetic glucocor-
ticoids by assessing biosynthesis, secretion, and biological
activity of diverse hpa axis secretagogues and the ontog-
eny, number, and function of their respective receptors,
including, if feasible, postmortem analyses of program-
ming and brain morphology; 6) further studies looking at
the clinical implications of fetal and infant hpa axis
suppression after exposure to synthetic glucocorticoids
in utero; and 7) evaluating whether exposure to syn-
thetic glucocorticoids in utero constitutes a valid model
of intrauterine exposure to maternal stress.
Furthermore, extrapolation from animals to humans
may help guiding and interpreting human studies and can
provide support for the human evidence. Most impor-
tantly, animal studies have the advantage of being exper-
imentally controlled and allow scrutinizing the mecha-
nisms underlying the observed effects of glucocorticoids
on hpa axis (e.g., see Section V.C).
In the offspring of rodents, early exposure to synthetic
glucocorticoids blunts both hpa basal activity and stressor
reactivity during the neonatal period and in later life (e.g.,
Refs. 247–249). However, in a larger number of studies,
early exposure to synthetic glucocorticoids has been
linked to hpa hyperactivity in various species, including
nonhuman primates, and at different life stages (e.g., Refs.
250–254). Taken together, data from animal studies in-
dicate that lifelong hpa axis dysregulation, rather than
either static hypoactivity or hyperactivity of hpa axis, is a
common consequence of early exposure to synthetic glu-
cocorticoids (4, 5, 7, 18, 21, 255). A more detailed com-
parison between the human and animal literature is ur-
gently needed. This comparison should especially take
into account the differences between species such as rats,
rabbits, and mice, where the hpa axis primarily matures
postnatally, and species such as primates, sheep, and
guinea pigs, where hpa axis maturation primarily occurs
prenatally (96).
VI. Summary and Conclusions
Exposure to synthetic glucocorticoids in utero reduces fe-
tal and, in some cases, newborn and infant hpa activity
under basal conditions, and,more consistently, after pain-
related stress. These effects may depend on the total
amount of glucocorticoids administered and the time that
elapses between glucocorticoid exposure and hpa axis as-
sessment.Althoughbaselinehpa function seems to recover
within the first 2 wk postpartum, there is initial evidence
that blunted hpa axis reactivity to pain-related stress per-
sists throughout the first 4 months. It remains unclear,
however,whether exposure to synthetic glucocorticoids in
utero profoundly influences hpa function beyond the first
months postpartum into adult life. Emerging evidence in-
dicates that early dysregulation of hpa axis is adverse,
possibly leading to compromised development and health
in the short term. It is as yet unclear as to whether long-
termhealth disturbances are to be expected. Specific phar-
macokinetic properties of synthetic glucocorticoids and
their impact on placental 11-HSD2 activity both deter-
mine the amount of substance that passes frommother to
fetus. Themechanisms of glucocorticoid-induced changes
in hpa axis function are complex, including possible al-
terations at subcortical and cortical levels of the brain.
Finally, it remains to be answered whether the endocrine
effects of synthetic glucocorticoids in utero shed light on
the impact ofmaternal gestational stress on fetal and new-
born endocrine function. Early dysregulation of hpa axis
after intrauterine exposure to glucocorticoids may be a
mechanism leading to compromised development and
health. More randomized human follow-up studies are
needed to better understand the short- and long-term
effects of antenatal exposure to synthetic or endogenous
glucocorticoids on the offspring’s hpa axis and poten-
tial short- and long-term consequences on health and
development.
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